HRP970453A2 - Arylsulfonylamino hydroxamic acid derivatives - Google Patents
Arylsulfonylamino hydroxamic acid derivativesInfo
- Publication number
- HRP970453A2 HRP970453A2 HR60/024,675A HRP970453A HRP970453A2 HR P970453 A2 HRP970453 A2 HR P970453A2 HR P970453 A HRP970453 A HR P970453A HR P970453 A2 HRP970453 A2 HR P970453A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- aryl
- amino
- heteroaryl
- benzenesulfonyl
- Prior art date
Links
- -1 Arylsulfonylamino hydroxamic Chemical compound 0.000 title claims description 78
- 239000002253 acid Substances 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims description 80
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 60
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 26
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 26
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 230000005764 inhibitory process Effects 0.000 claims description 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 14
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 208000028169 periodontal disease Diseases 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 230000036303 septic shock Effects 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 206010039705 Scleritis Diseases 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 claims description 4
- YYGXSXMKOALHSY-UHFFFAOYSA-N ethyl 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)C1CCCCC1 YYGXSXMKOALHSY-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 229940080818 propionamide Drugs 0.000 claims description 4
- RDPDVZHMIQZOOF-UHFFFAOYSA-N 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C1CCCCC1)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 RDPDVZHMIQZOOF-UHFFFAOYSA-N 0.000 claims description 3
- VJHJDEUUCPMADI-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-yl 3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonylamino]propanoate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C1CCCCC1)C(=O)NO)CCC(=O)OC1=CC=C(CCC2)C2=C1 VJHJDEUUCPMADI-UHFFFAOYSA-N 0.000 claims description 3
- 150000008575 L-amino acids Chemical class 0.000 claims description 3
- IIRGRPFADBGAGK-UHFFFAOYSA-N [1-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl] acetate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCC(OC(C)=O)CC1 IIRGRPFADBGAGK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- FDDVYQSFBLLBLU-UHFFFAOYSA-N n-hydroxy-2-[[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCC(O)CC1 FDDVYQSFBLLBLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 claims description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims description 2
- ACFCRTQFMQXAHZ-UHFFFAOYSA-N 2-[4-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperazin-1-yl]ethyl 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCN(CCOC(=O)C(C)(C)C)CC1 ACFCRTQFMQXAHZ-UHFFFAOYSA-N 0.000 claims description 2
- POHLQQJCUDBBFW-UHFFFAOYSA-N 2-[4-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperazin-1-yl]ethyl benzoate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCN(CCOC(=O)C=2C=CC=CC=2)CC1 POHLQQJCUDBBFW-UHFFFAOYSA-N 0.000 claims description 2
- RVXABMHTWPAPCO-UHFFFAOYSA-N 2-[[4-(4-butylphenoxy)phenyl]sulfonyl-[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]amino]-n-hydroxy-3-methylbutanamide Chemical compound C1=CC(CCCC)=CC=C1OC1=CC=C(S(=O)(=O)N(CCC(=O)N2CCC(O)CC2)C(C(C)C)C(=O)NO)C=C1 RVXABMHTWPAPCO-UHFFFAOYSA-N 0.000 claims description 2
- DGHRLJNUXXHBBJ-UHFFFAOYSA-N 2-cyclohexyl-2-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]amino]-n-hydroxyacetamide Chemical compound C1CC(O)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC=2C=CC(F)=CC=2)=CC=1)C(C(=O)NO)C1CCCCC1 DGHRLJNUXXHBBJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000005110 aryl thio group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- IYBFAWXEVQJOOK-UHFFFAOYSA-N ethoxycarbonyloxymethyl 3-[(1-amino-2-hydroxy-3-methyl-1-oxobutan-2-yl)-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonylamino]propanoate Chemical compound C(C)OC(=O)OCOC(CCN(C(C(C)C)(O)C(N)=O)S(=O)(=O)C1=CC=C(C=C1)OCC1=CC=C(C=C1)F)=O IYBFAWXEVQJOOK-UHFFFAOYSA-N 0.000 claims description 2
- OXEVBTQXBUGVOZ-UHFFFAOYSA-N ethoxycarbonyloxymethyl 3-[[1-(hydroxyamino)-1-oxohexan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoate Chemical compound CCOC(=O)OCOC(=O)CCN(C(CCCC)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 OXEVBTQXBUGVOZ-UHFFFAOYSA-N 0.000 claims description 2
- OTXRGOWUZRTWRY-UHFFFAOYSA-N ethoxycarbonyloxymethyl 3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonylamino]propanoate Chemical compound C=1C=C(OC)C=CC=1S(=O)(=O)N(CCC(=O)OCOC(=O)OCC)C(C(=O)NO)C1CCCCC1 OTXRGOWUZRTWRY-UHFFFAOYSA-N 0.000 claims description 2
- KFJNJNHLFOYCEH-UHFFFAOYSA-N ethyl 4-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperazine-2-carboxylate Chemical compound C1CNC(C(=O)OCC)CN1C(=O)CCN(C(C(C)C)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 KFJNJNHLFOYCEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 2
- PELDTXBSNDSZOG-UHFFFAOYSA-N n-hydroxy-2-[[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-(4-phenylmethoxyphenyl)sulfonylamino]-3-methylbutanamide Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCC(O)CC1 PELDTXBSNDSZOG-UHFFFAOYSA-N 0.000 claims description 2
- FGEAIMWSTJVRJE-UHFFFAOYSA-N n-hydroxy-2-[[3-[4-(2-hydroxy-2-methylpropyl)piperazin-1-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCN(CC(C)(C)O)CC1 FGEAIMWSTJVRJE-UHFFFAOYSA-N 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- GRSGSWSMFLUWKY-UHFFFAOYSA-N 2-hydroxy-2-[[3-[5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(O)(C(C)C)C(N)=O)CCC(=O)N1C(CN2CCO)CC2C1 GRSGSWSMFLUWKY-UHFFFAOYSA-N 0.000 claims 1
- SRDRYTRKCQSMKY-UHFFFAOYSA-N acetamide;benzoic acid Chemical compound CC(N)=O.OC(=O)C1=CC=CC=C1 SRDRYTRKCQSMKY-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000007858 starting material Substances 0.000 description 36
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 108060005980 Collagenase Proteins 0.000 description 17
- 102000029816 Collagenase Human genes 0.000 description 17
- 229960002424 collagenase Drugs 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 13
- 125000004494 ethyl ester group Chemical group 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 12
- HDSKIPUGIPWRCI-UHFFFAOYSA-N methyl(piperidin-4-yl)carbamic acid Chemical compound OC(=O)N(C)C1CCNCC1 HDSKIPUGIPWRCI-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 108091007196 stromelysin Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010026132 Gelatinases Proteins 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- OGKKORGKSRNYDJ-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium;fluoro(dioxido)borane Chemical compound [O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 OGKKORGKSRNYDJ-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- PEHSSTUGJUBZBI-UHFFFAOYSA-N indan-5-ol Chemical compound OC1=CC=C2CCCC2=C1 PEHSSTUGJUBZBI-UHFFFAOYSA-N 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 230000006433 tumor necrosis factor production Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- SHNSLRXSEFORQY-UHFFFAOYSA-N 3-[(1-cyclohexyl-2-oxo-2-phenylmethoxyethyl)-(4-methoxyphenyl)sulfonylamino]propanoic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CCC(O)=O)C(C(=O)OCC=1C=CC=CC=1)C1CCCCC1 SHNSLRXSEFORQY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 108050005238 Collagenase 3 Proteins 0.000 description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 2
- 229930182831 D-valine Natural products 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- VYUUSHZDXZJKJK-UHFFFAOYSA-N [1-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl] benzoate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCC(OC(=O)C=2C=CC=CC=2)CC1 VYUUSHZDXZJKJK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- CTGYVPSWKHOVGS-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)CC1=CC=CC=C1 CTGYVPSWKHOVGS-UHFFFAOYSA-N 0.000 description 2
- MAMNDUQFRXZBEB-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-1-oxo-4-phenylbutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)CCC1=CC=CC=C1 MAMNDUQFRXZBEB-UHFFFAOYSA-N 0.000 description 2
- ZRRYJSXXZRUBQI-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-1-oxohexan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C=1C=C(OC)C=CC=1S(=O)(=O)N(C(CCCC)C(=O)NO)CCC(=O)N1CCC(C(=O)OCC)CC1 ZRRYJSXXZRUBQI-UHFFFAOYSA-N 0.000 description 2
- KXIBSURCHSFPGU-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(C(COC(C)(C)C)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 KXIBSURCHSFPGU-UHFFFAOYSA-N 0.000 description 2
- IZGJLFMWBDCFDE-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(C(C(C)C)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 IZGJLFMWBDCFDE-UHFFFAOYSA-N 0.000 description 2
- HPMCUAGHXZZMRD-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-3-naphthalen-1-yl-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)CC1=CC=CC2=CC=CC=C12 HPMCUAGHXZZMRD-UHFFFAOYSA-N 0.000 description 2
- ZLMGBTRQPJCTII-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-4,4-dimethyl-1-oxopentan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(C(CC(C)(C)C)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 ZLMGBTRQPJCTII-UHFFFAOYSA-N 0.000 description 2
- IGMXFXOPTWUSGT-UHFFFAOYSA-N ethyl 1-[3-[[1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(C(CC(C)C)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 IGMXFXOPTWUSGT-UHFFFAOYSA-N 0.000 description 2
- ZOPSELVAAZYZDL-UHFFFAOYSA-N ethyl 1-[3-[[3-(4-fluorophenyl)-1-(hydroxyamino)-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)CC1=CC=C(F)C=C1 ZOPSELVAAZYZDL-UHFFFAOYSA-N 0.000 description 2
- QLUVZGKCSWWMPE-UHFFFAOYSA-N ethyl 1-[3-[[3-cyclohexyl-1-(hydroxyamino)-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)CC1CCCCC1 QLUVZGKCSWWMPE-UHFFFAOYSA-N 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- RBDLVWKFDNTTGT-UHFFFAOYSA-N n-hydroxy-2-[[3-[4-(2-hydroxyethyl)piperazin-1-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCN(CCO)CC1 RBDLVWKFDNTTGT-UHFFFAOYSA-N 0.000 description 2
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- QHWVASUHXPOWQV-UHFFFAOYSA-N tert-butyl n-[[1-[3-[[1-(hydroxyamino)-1-oxohexan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C=1C=C(OC)C=CC=1S(=O)(=O)N(C(CCCC)C(=O)NO)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 QHWVASUHXPOWQV-UHFFFAOYSA-N 0.000 description 2
- KMIAEOILDGTBQR-UHFFFAOYSA-N tert-butyl n-[[1-[3-[[1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 KMIAEOILDGTBQR-UHFFFAOYSA-N 0.000 description 2
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- XWHHYOYVRVGJJY-MRVPVSSYSA-N (2r)-2-amino-3-(4-fluorophenyl)propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-MRVPVSSYSA-N 0.000 description 1
- WAMWSIDTKSNDCU-SSDOTTSWSA-N (2r)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@H](N)C1CCCCC1 WAMWSIDTKSNDCU-SSDOTTSWSA-N 0.000 description 1
- OFYAYGJCPXRNBL-GFCCVEGCSA-N (2r)-2-azaniumyl-3-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(C[C@@H]([NH3+])C([O-])=O)=CC=CC2=C1 OFYAYGJCPXRNBL-GFCCVEGCSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical group C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- PNWCJLFRYRHCFB-UHFFFAOYSA-N 1-(4-methoxyphenyl)-n-[(4-methoxyphenyl)methoxy]methanamine Chemical compound C1=CC(OC)=CC=C1CNOCC1=CC=C(OC)C=C1 PNWCJLFRYRHCFB-UHFFFAOYSA-N 0.000 description 1
- YRAQDWXTCRFBCH-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC=1C=CC=CC=1)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 YRAQDWXTCRFBCH-UHFFFAOYSA-N 0.000 description 1
- SKGUYPVXEAISOV-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-1-oxo-4-phenylbutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CCC=1C=CC=CC=1)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 SKGUYPVXEAISOV-UHFFFAOYSA-N 0.000 description 1
- BGVTUKWGXYQZHC-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-1-oxohexan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C=1C=C(OC)C=CC=1S(=O)(=O)N(C(CCCC)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 BGVTUKWGXYQZHC-UHFFFAOYSA-N 0.000 description 1
- BIUUGGXBTBXBOS-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(COC(C)(C)C)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 BIUUGGXBTBXBOS-UHFFFAOYSA-N 0.000 description 1
- YUXHBNUHSNIPFG-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 YUXHBNUHSNIPFG-UHFFFAOYSA-N 0.000 description 1
- WMOPNSHPFSYFBG-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-3-naphthalen-1-yl-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC=1C2=CC=CC=C2C=CC=1)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 WMOPNSHPFSYFBG-UHFFFAOYSA-N 0.000 description 1
- AXDFZSSQKHOQAE-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-4,4-dimethyl-1-oxopentan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)(C)C)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 AXDFZSSQKHOQAE-UHFFFAOYSA-N 0.000 description 1
- HYSUMCNOZYLCEP-UHFFFAOYSA-N 1-[3-[[1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 HYSUMCNOZYLCEP-UHFFFAOYSA-N 0.000 description 1
- KREIHJCFQOQLNG-UHFFFAOYSA-N 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid;hydrate Chemical compound O.C1=CC(OC)=CC=C1S(=O)(=O)N(C(C1CCCCC1)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 KREIHJCFQOQLNG-UHFFFAOYSA-N 0.000 description 1
- WANCQPPDTBTLNZ-UHFFFAOYSA-N 1-[3-[[3-(4-fluorophenyl)-1-(hydroxyamino)-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC=1C=CC(F)=CC=1)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 WANCQPPDTBTLNZ-UHFFFAOYSA-N 0.000 description 1
- WUGVBPQXSXZJKP-UHFFFAOYSA-N 1-[3-[[3-cyclohexyl-1-(hydroxyamino)-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC1CCCCC1)C(=O)NO)CCC(=O)N1CCC(C(O)=O)CC1 WUGVBPQXSXZJKP-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- VCOPVGXXRFZZHS-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-yl 3-[[1-(hydroxyamino)-1-oxohexan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoate Chemical compound C=1C=C2CCCC2=CC=1OC(=O)CCN(C(CCCC)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 VCOPVGXXRFZZHS-UHFFFAOYSA-N 0.000 description 1
- GOPUHTXVZGIOHN-UHFFFAOYSA-N 2,4-dihydroxybenzohydrazide Chemical compound NNC(=O)C1=CC=C(O)C=C1O GOPUHTXVZGIOHN-UHFFFAOYSA-N 0.000 description 1
- HYWNUHYYWGKMIP-UHFFFAOYSA-N 2-[4-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperazin-1-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCN(CC(O)=O)CC1 HYWNUHYYWGKMIP-UHFFFAOYSA-N 0.000 description 1
- FFKFSKOHASKXKI-UHFFFAOYSA-N 2-[[3-(2-amino-4-methylpiperidin-1-yl)-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-2-cyclohexyl-n-hydroxyacetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C1CCCCC1)C(=O)NO)CCC(=O)N1C(N)CC(C)CC1 FFKFSKOHASKXKI-UHFFFAOYSA-N 0.000 description 1
- RXYQSJIVPDYLMG-UHFFFAOYSA-N 2-[[3-[4-(2-hydroxyethyl)piperazin-1-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methyl-n-phenylmethoxybutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NOCC=1C=CC=CC=1)CCC(=O)N1CCN(CCO)CC1 RXYQSJIVPDYLMG-UHFFFAOYSA-N 0.000 description 1
- OPSWCIWXWHYPSM-UHFFFAOYSA-N 2-[[3-[4-(2-hydroxyethyl)piperazin-1-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methyl-n-phenylmethoxybutanamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NOCC=1C=CC=CC=1)CCC(=O)N1CCN(CCO)CC1 OPSWCIWXWHYPSM-UHFFFAOYSA-N 0.000 description 1
- ZBWJOCMVXRKGEN-UHFFFAOYSA-N 2-[[3-[4-(2-hydroxyethyl)piperazin-1-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methylbutanoic acid;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(O)=O)CCC(=O)N1CCN(CCO)CC1 ZBWJOCMVXRKGEN-UHFFFAOYSA-N 0.000 description 1
- QNNAUWITTHMABY-UHFFFAOYSA-N 2-[[3-[4-(dimethylamino)piperidin-1-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCC(N(C)C)CC1 QNNAUWITTHMABY-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- IIVQAZHUVWRZHJ-UHFFFAOYSA-N 2-cyclohexyl-n-hydroxy-2-[[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C1CCCCC1)C(=O)NO)CCC(=O)N1CCC(O)CC1 IIVQAZHUVWRZHJ-UHFFFAOYSA-N 0.000 description 1
- WRJZKSHNBALIGH-UHFFFAOYSA-N 2-piperazin-1-ium-1-ylacetate Chemical compound OC(=O)CN1CCNCC1 WRJZKSHNBALIGH-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- LWEOFVINMVZGAS-UHFFFAOYSA-N 3-piperazin-1-ylpropan-1-ol Chemical compound OCCCN1CCNCC1 LWEOFVINMVZGAS-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- XQCOLPMZLCMDHQ-UHFFFAOYSA-N CCNCC.CN(C)C.N Chemical compound CCNCC.CN(C)C.N XQCOLPMZLCMDHQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UYGJJZHSQFXRGS-UHFFFAOYSA-N N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-[3-oxo-3-(4-piperidin-1-ylpiperidin-1-yl)propyl]amino]-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCC(N2CCCCC2)CC1 UYGJJZHSQFXRGS-UHFFFAOYSA-N 0.000 description 1
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- RCQIYRYMNTWPPW-UHFFFAOYSA-N [1-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl] butanoate Chemical compound C1CC(OC(=O)CCC)CCN1C(=O)CCN(C(C(C)C)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 RCQIYRYMNTWPPW-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- TXMKOYLWBOAWDY-GFCCVEGCSA-N benzyl (2R)-2-amino-4,4-dimethylpentanoate Chemical compound CC(C)(C)C[C@@H](N)C(=O)OCC1=CC=CC=C1 TXMKOYLWBOAWDY-GFCCVEGCSA-N 0.000 description 1
- YIRBOOICRQFSOK-LLVKDONJSA-N benzyl (2r)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-LLVKDONJSA-N 0.000 description 1
- MBRRYUQWSOODEO-GFCCVEGCSA-N benzyl (2r)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-GFCCVEGCSA-N 0.000 description 1
- VHHCAGBVYBIOCK-GFCCVEGCSA-N benzyl (2r)-2-aminohexanoate Chemical compound CCCC[C@@H](N)C(=O)OCC1=CC=CC=C1 VHHCAGBVYBIOCK-GFCCVEGCSA-N 0.000 description 1
- KUXQHCVDBXSFRD-UHFFFAOYSA-N benzyl 2-[3-[tert-butyl(dimethyl)silyl]oxypropyl-(4-methoxyphenyl)sulfonylamino]-2-cyclohexylacetate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CCCO[Si](C)(C)C(C)(C)C)C(C(=O)OCC=1C=CC=CC=1)C1CCCCC1 KUXQHCVDBXSFRD-UHFFFAOYSA-N 0.000 description 1
- VENXMXVEBZOCBD-UHFFFAOYSA-N benzyl 2-cyclohexyl-2-[3-hydroxypropyl-(4-methoxyphenyl)sulfonylamino]acetate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CCCO)C(C(=O)OCC=1C=CC=CC=1)C1CCCCC1 VENXMXVEBZOCBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- ORQXBVXKBGUSBA-UHFFFAOYSA-N cyclohexyl D-alanine Natural products OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- ARSWXVLOEZBZOB-UHFFFAOYSA-N ethyl 2-[4-[3-[[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperazin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCN1C(=O)CCN(C(C(C)C)C(=O)NO)S(=O)(=O)C1=CC=C(OC)C=C1 ARSWXVLOEZBZOB-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical compound CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
- AZGHHWRSCIFWPU-UHFFFAOYSA-N n-hydroxy-2-[(4-methoxyphenyl)sulfonyl-[3-[4-(methylamino)piperidin-1-yl]-3-oxopropyl]amino]-3-phenylpropanamide;hydrochloride Chemical compound Cl.C1CC(NC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)CC1=CC=CC=C1 AZGHHWRSCIFWPU-UHFFFAOYSA-N 0.000 description 1
- PNXMERLHALEIGH-UHFFFAOYSA-N n-hydroxy-2-[(4-methoxyphenyl)sulfonyl-[3-[4-(methylamino)piperidin-1-yl]-3-oxopropyl]amino]-4-phenylbutanamide;hydrochloride Chemical compound Cl.C1CC(NC)CCN1C(=O)CCN(S(=O)(=O)C=1C=CC(OC)=CC=1)C(C(=O)NO)CCC1=CC=CC=C1 PNXMERLHALEIGH-UHFFFAOYSA-N 0.000 description 1
- YOFGCLSUGZMCGZ-UHFFFAOYSA-N n-hydroxy-2-[[3-[4-(3-hydroxypropyl)piperazin-1-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1CCN(CCCO)CC1 YOFGCLSUGZMCGZ-UHFFFAOYSA-N 0.000 description 1
- OMXMBCMXAHCFCQ-UHFFFAOYSA-N n-hydroxy-2-[[3-[5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-3-oxopropyl]-(4-methoxyphenyl)sulfonylamino]-3-methylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C(C)C)C(=O)NO)CCC(=O)N1C(CN2CCO)CC2C1 OMXMBCMXAHCFCQ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 108010052605 prostromelysin Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- TWTYDVMFTUTDDD-UHFFFAOYSA-N tert-butyl n-[[1-[3-[(3-amino-1-hydroxy-2-naphthalen-1-yl-3-oxopropyl)-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(O)C(C(N)=O)C=1C2=CC=CC=C2C=CC=1)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 TWTYDVMFTUTDDD-UHFFFAOYSA-N 0.000 description 1
- VHGRPQZJYNLTCR-UHFFFAOYSA-N tert-butyl n-[[1-[3-[[1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC=1C=CC=CC=1)C(=O)NO)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 VHGRPQZJYNLTCR-UHFFFAOYSA-N 0.000 description 1
- CZCPDXYAIURWOM-UHFFFAOYSA-N tert-butyl n-[[1-[3-[[1-(hydroxyamino)-1-oxo-4-phenylbutan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CCC=1C=CC=CC=1)C(=O)NO)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 CZCPDXYAIURWOM-UHFFFAOYSA-N 0.000 description 1
- VTSUEEVNZFJQCX-UHFFFAOYSA-N tert-butyl n-[[1-[3-[[1-(hydroxyamino)-4,4-dimethyl-1-oxopentan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)(C)C)C(=O)NO)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 VTSUEEVNZFJQCX-UHFFFAOYSA-N 0.000 description 1
- NXFJYRUCPDHCSA-UHFFFAOYSA-N tert-butyl n-[[1-[3-[[1-cyclohexyl-2-oxo-2-(phenylmethoxyamino)ethyl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C1CCCCC1)C(=O)NOCC=1C=CC=CC=1)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 NXFJYRUCPDHCSA-UHFFFAOYSA-N 0.000 description 1
- YOVDWRMKQBQTGF-UHFFFAOYSA-N tert-butyl n-[[1-[3-[[3-(4-fluorophenyl)-1-(hydroxyamino)-1-oxopropan-2-yl]-(4-methoxyphenyl)sulfonylamino]propanoyl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC=1C=CC(F)=CC=1)C(=O)NO)CCC(=O)N1CCC(CNC(=O)OC(C)(C)C)CC1 YOVDWRMKQBQTGF-UHFFFAOYSA-N 0.000 description 1
- DJJOYDXRUBOZON-UHFFFAOYSA-N tert-butyl n-methyl-n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1CCNCC1 DJJOYDXRUBOZON-UHFFFAOYSA-N 0.000 description 1
- KTJOZDBANQOLHP-UHFFFAOYSA-N tert-butyl-(3-iodopropoxy)-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCI KTJOZDBANQOLHP-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- FKPIQXKEFGLMNA-UHFFFAOYSA-N trimethyl-[2-(2-trimethylsilylethoxy)ethyl]silane Chemical compound C[Si](C)(C)CCOCC[Si](C)(C)C FKPIQXKEFGLMNA-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Description
Stanje tehnike
Opisani izum odnosi se na derivate arilsulfonilamino hidroksamske kiseline, koji su inhibitori matričnih metaloproteinaza ili proizvodnje faktora tumorne nekroze (TNF), a kao takvi su primjenjivi u tretiranju stanja odabranog iz grupe koju čine artritis, karcinom, ulcer tkiva, restenozis, periodontalno oboljenje, epidermolizis buloza, skleritis i druga oboljenja karakterizirana aktivnošću matrične metaloproteinaze, AIDS, sepsis, sepstički šok i druga oboljenja koja obuhvaćaju proizvodnju TNF. Dodatno, spojevi opisanog izuma mogu se koristiti u kombiniranoj terapiji sa standardnim ne-steroidnim anti-inflamatornim lijekovima (u daljnjem tekstu: NSAID'S) i analgeticima za tretiranje artritisa i u kombinaciji sa citotoksičnim lijekovima, takvim kao što su adriamicin, daunomicin, cis-platina, etopozid, taksol, taksoter i alkaloidi, takvi kao što je vinkristin, u tretiranju karcinoma.
Ovaj se izum također odnosi na postupak korištenja takvih spojeva u tretiranju gornjih oboljenja kod sisavaca, naročito kod ljudi i na farmaceutske preparate primjenjive za takav tretman.
Postoje brojni enzimi koji vrše strukturno raskidanje proteina i koji su strukturno slični metaloproteazama. Matrično-razlažujuće metaloproteinaze, takve kao što su želatinaza, stromelizin i kolagenaza učestvuju u tkivnoj matričnoj degradaciji (npr. kolagenski kolaps) i učestvuju u mnogim patološkim stanjima koja obuhvaćaju nenormalan metabolizam vezivnog tkiva i matrice bazne membrane, takvim kao što su artritis (npr. osteoartritis i reumatoidni artritis), ulcer tkiva (npr. kornealni, epidermalni i gastrični ulcer), nenormalno zacjeljenje rana, periodontalno oboljenje, koštano oboljenje (npr. Paget-ovo oboljenje i osteoporoza), tumorna matastaza ili invazija, kao i HIV-infekcija (J. Leuk. Biol., 52 (2), 244 - 248, 1992.).
Poznato je da faktor tumorne nekroze učestvuje u mnogim infektivnim i autoimunim oboljenjima (W. Fiers, FEBS Letters, 1991., 285, 199). Dalje je pokazano, da je TNF primarni uzročnik inflamatornog odgovora koji se opaža kod sepse i sepstičnog šoka (C.E. Spooner, i dr., Clinical Immunology and Immunopathology, 1992., 62, S11).
Kratki opis izuma
Opisani izum se odnosi na spoj formule:
[image]
ili njegove farmaceutski prihvatljive soli, gdje
n je 1 do 6;
X je OR1, gdje je R1 kako je definirano niže: azetidinil, pirolidinil, piperidinil, morfolinil, tiomorfolinil, indolinil, izoindolinil, tetrahidrohinolinil, tetrahidroizohinolinil, piperazinil ili premošten diazabicikloalkil prsten odabran iz grupe koju čine:
[image]
gdje r je 1, 2 ili 3;
m je 1 ili 2; i
p je 0 ili 1;
gdje svaka heterociklična grupa može po izboru biti supstituirana sa jednom ili dvije grupe odabranih između hidroksi, (C1-C6)alkil, (C1-C6)alkoksi, (C1-C10)acil, (C1-C10)aciloksi, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkil, hidroksi (C1-C6)alkil, (C1-C6)alkoksi (C1-C6)alkil, (C1-C6)aciloksi (C1-C6)alkil, (C1-C6)alkiltio, (C1-C6)alkiltio (C1-C6)alkil, (C6-C10)ariltio, (C6-C10)ariltio (C1-C6)alkil, R9R10N, R9R10NSO2, R9R10NCO, R9R10NCO (C1-C6)alkil, gdje su R9 i R10 svaki nezavisno vodik, (C1-C6)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil ili (C5-C9)heteroaril (C1-C6)alkil, ili R9 i R10 mogu zajedno sa atomom dušika na koji su spojeni formirati azetidinil, pirolidinil, piperidinil, morfolinil ili tiomorfolinil prsten; R12SO2, R12SO2NH, gdje je R12 trifluorometil, (C1-C6)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil ili (C5-C9)heteroaril (C1-C6)alkil; R13CONR9, gdje je R9 kako je definirano naprijed i R13 je vodik, (C1-C6)alkil, (C1-C6)alkoksi, (C6-C10)aril, (C5-C9)heteroaril, (C1-C6)aril (C1-C6)alkil (C6-C10)aril (C1-C6)alkoksi ili (C5-C9)heteroaril (C1-C6)alkil; R14OOC, R14OOC (C1-C6)alkil, gdje R14 je (C1-C6)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, 5-indanil, CHR5OCOR6, gdje je R15 vodik ili (C1-C6)alkil i R6 je (C1-C6)alkil, (C1-C6)alkoksi ili (C6-C10)aril; CH2CONR7R8, gdje su R7 i R8 svaki nezavisno vodik, (C1-C6)alkil, ili mogu zajedno sa atomom dušika na koji su vezani formirati azetidinil, pirolidinil, piperidinil, morfolinil ili tiomorfolinil prsten; ili R15O(C1-C6) alkil, gdje R15 je H2N(CHR16)CO, gdje je R16 bočni lanac prirodne D- ili L-amino kiseline;
R1 je (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, 5-indanil, CHR5OCOR6 ili CH2CONR7R8, gdje su R5, R6, R7 i R8 kako je definirano naprijed;
R3 i R4 se svaki nezavisno bira iz grupe koju čine vodik, (C1-C6)alkil, trifluorometil, trifluorometil (C1-C6)alkil, (C1-C6)alkil (difluorometilen), C1-C3)alkil (difluorometilen) C1-C3)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkil, (C6-C10)aril (C6-C10)aril, (C6-C10)aril (C6-C10)aril (C1-C6)alkil, (C3-C6)cikloalkil, (C3-C6)cikloalkil (C1-C6)alkil, hidroksi (C1-C6)alkil, (C1-C10)aciloksi (C1-C6)alkil, (C1-C6)aciloksi (C1-C6)alkil, (C1-C10)acilamino (C1-C6)alkil, piperidil, (C1-C6)alkil piperidil, (C6-C10)aril (C1-C6)alkoksi (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkoksi (C1-C6)alkil, (C1-C6)alkiltio (C1-C6)alkil, (C6-C10)ariltio (C1-C6)alkil, (C1-C6)alkilsulfinil (C1-C6)alkil, (C6-C10)arilsulfinil (C1-C6)alkil, (C6-C10)arilsulfonil (C1-C6)alkil, amino (C1-C6)alkil, (C1-C6)alkilamino (C1-C6)alkil, ((C1-C6)alkilamino)2 (C1-C6)alkil, R17CO(C1-C6)alkil, gdje R17 je R14O ili R7R8N, gdje su R7, R8 i R14 kako je definirano naprijed; ili R18(C1-C6)alkil, gdje je R18 piperazinil, (C1-C10)acil piperazinil, (C6-C10)aril piperazinil, (C5-C9)heteroaril piperazinil, (C1-C6)alkil piperazinil, (C6-C10)aril (C1-C6)alkilpiperazinil, (C5-C9)heteroaril (C1-C6)alkilpiperazinil, morfolinil, tiomorfolinil, piperidinil, pirolidinil, piperidil, (C1-C6)alkil piperidil, (C6-C10)aril piperidil, (C5-C9)heteroaril piperidil, (C6-C10)aril (C1-C6)alkilpiperidil, (C5-C9)heteroaril (C1-C6)alkilpiperidil ili (C1-C10)acilpiperidil; ili
R3 i R4 mogu zajedno formirati (C3-C6)cikloalkil, oksacikloheksil, tiocikloheksil, indanil ili tetralinil prsten ili grupu formule
[image]
gdje je R21 vodik, (C1-C10)acil, (C1-C6)alkil, (C6-C10)aril (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkil ili (C1-C6)alkilsulfonil; i
Q je (C1-C6)alkil, (C6-C10)aril, (C6-C10)ariloksi (C6-C10)aril, (C6-C10)aril (C6-C10)aril, (C6-C10)aril (C6-C10)aril (C1-C6)alkil, (C6-C10)ariloksi (C5-C9)heteroaril, (C5-C9)heteroaril, (C1-C6)alkil (C6-C10)aril, (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C1-C6)alkil, (C5-C9)heteroariloksi (C6-C10)aril, (C1-C6)alkil (C5-C9)heteroaril, (C1-C6)alkoksi (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkoksi (C5-C9)heteroaril, (C5-C9)heteroariloksi (C5-C9)heteroaril, (C6-C10)ariloksi (C1-C6)alkil, (C5-C9)heteroariloksi (C1-C6)alkil, (C1-C6)alkil (C6-C10)ariloksi (C6-C10)aril, (C1-C6)alkil (C5-C9)heteroariloksi (C6-C10)aril, (C1-C6)alkil (C6-C10)ariloksi (C5-C9)heteroaril, (C1-C6)alkoksi (C6-C10)ariloksi (C6-C10)aril, (C1-C6)alkoksi (C5-C9)hetreoariloksi (C6-C10)aril ili (C1-C6)alkoksi (C6-C10)ariloksi (C5-C9)heteroaril, gdje je svaka aril grupa po izboru supstituirana sa fluoro, kloro, bromo, (C1-C6)alkil, (C1-C6)alkoksi ili perfluoro (C1-C6)alkil;
uz pretpostavku da X mora biti supstituiran kada je definiran kao azetidinil, pirolidinil, morfolinil, tiomorfolinil, indolinil, izoidnolinil, tetrahidrohinolinil tetrahidroizohinolinil, piperazinil, (C1-C10)acilpiperazinil, (C1-C6) alkilpiperazinil, (C6-C10)arilpiparazinil, (C5-C9)heteroarilpiperazinil ili premošten diazabicikloalkil prsten.
Termin “alkil”, kako je korišteno ovdje, ako nije drugačije naglašeno, uključuje zasićene monovalentne ugljikovodične radikale koji imaju normalne, račvaste ili ciklične dijelove ili njihove kombinacije.
Termin “alkoksi”, kako je korišteno ovdje, uključuje O-alkil grupe gdje je “alkil” kako je definirano naprijed.
Termin “aril”, kako je korišteno ovdje, ako nije drugačije naznačeno, uključuje organski radikal izveden iz aromatičnog ugljika uklanjanjem jednog vodika, takvog kao što je fenil ili naftil, po izboru supstituiran sa 1 do 3 supstituenata odabranih iz grupe koju čine fluoro, kloro, trifluorometil, (C1-C6)alkoksi, (C6-C10)ariloksi, trifluorometoksi, difluorometoksi i (C1-C6)alkil.
Termin “heteroaril”, kako je korišteno ovdje, ako nije drugačije naglašeno, uključuje organski derivat izveden iz aromatičnog heterocikličnog spoja uklanjanjem jednog vodika, takvog kao što je piridil, furil, piroil, tienil, izotienil, izotiazolil, imidazolil, benzimidazolil, tetrazolil, pirazinil, pirimidil, hinolil, izohinolil, benzofuril, izobenzofuril, benzotienil, pirazolil, indolil, izoindolil, purinil, karbazolil, izoksazolil, tiazolil, oksazolil, benzotiazolil ili benzoksazolil, po izboru supstituiran sa 1 do 2 supstituenata odabranih iz grupe koju čine fluoro, kloro, trifluorometil, (C1-C6)alkoksi, (C6-C10)ariloksi, trifluorometoksi, difluorometoksi i (C1-C6)alkil.
Termin “acil” kako je korišteno ovdje, ako nije drugačije naglašeno, uključuje radikal opće formule RCO, gdje je R alkil, alkoksi, aril, arilalkil ili arilalkiloksi i termini “alkil” ili “aril” su kako je definirano naprijed.
Termin “aciloksi” kako je korišteno ovdje, uključuje O-acil grupe, gdje je “acil” definiran naprijed.
Termin “D- ili L-amino kiselina” kako je korišteno ovdje, ako nije drugačije naglašeno, uključuje glicin, alanin, valin, leuicin, izoleucin, fenilalanin, asparagin, glutamin, triptofan, prolin, serin, treonin, tirozin, hidroksiprolin, cistein, cistin, metionin, aspartinsku kiselinu, lizin, arginin ili histidin.
Spojevi formule I mogu imati čiralne centre, i stoga postojati u različitim enantiomernim oblicima. Ovaj izum odnosi se na sve optičke izomere i stereoizomere spojeva formule I i na njihove smjese.
Poželjni spojevi formule I uključuju one, gdje n je 2.
Drugi poželjni spojevi formule I uključuju one, gdje bilo koji od R3 ili R4 nije vodik.
Drugi poželjni spojevi formule I uključuju one, gdje Ar je (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C6-C10)aril, 4-fluorofenoksi (C6-C10)aril, 4-fluorobenziloksi (C6-C10)aril ili (C1-C6)alkil (C6-C10)ariloksi (C6-C10)aril.
Drugi poželjni spojevi formule I uključuju one, gdje je X indolinil ili piperidinil.
Još poželjniji spojevi formule I uključuju one, gdje n je 2; bilo koji od R3 ili R4 nije vodik; Ar je (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C6-C10)aril, 4-fluorofenoksi (C6-C10)aril, 4-fluorobenziloksi (C6-C10)aril ili (C1-C6)alkil (C6-C10)ariloksi (C6-C10)aril; i X je indolinil ili piperidinil.
Specifični poželjni spojevi formule I uključuju slijedeće spojeve:
indan-5-il estar 3-[(cikloheksilhidroksikarbamoilmetil)-(4-metoksibenzensulfonil)-amino]-propionske kiseline;
1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzen-sulfonil)-amino]propionil}piperidin-4-il estar octene kiseline;
2-cikloheksil-N-hidroksi-2-[[3-(4-hidroksipiperidin-1-il)-3-okso-propil]-(4-metoksi-benzensulfonil)amino] acetamid;
1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzen-sulfonil)amino]propionil}piperidin-4-il estar benzoeve kiseline;
N-hidroksi-2-[[3-(4-hidroksipiperidin-1-il)-3-oksopropil]-(4-metoksi-benzensulfonil)amino]-3-metilbutiramid;
1-{3-[(cikloheksil-hidroksikarbamoil-metil)-(4-metoksi-benzen-sulfonil)-amino]propionil}piperidin-4-karboksilna kiselina;
etil estar 1-{3-[(cikloheksil-hidroksikarbamoil-metil)-(4-metoksi-benzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline;
2-cikloheksil-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-aminopiperidin-1-il)-3-oksipropil]amino} acetamid;
3-(4-klorofenil)-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-aminopiperidin-1-il)-3-oksipropil]amino} propionamid;
3-cikloheksil-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-aminopiperidin-1-il)-3-oksipropil] amino}propionamid;
N-hidroksi-2-[{3-[4-(2-hidroksi-2-metilpropil)piperazin-1-il]-3-oksopropil}-(4-metoksi-benzensulfonil)amino]-3-metilbutiramid;
2-(4-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzensulfonil)amino]propionil}piperazin-1-il)-etil estar 2,2-dimetilpropionske kiseline;
2-(4-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzensulfonil)-amino]propionil}piperazin-1-il)-etil estar benzoeve kiseline.
Drugi specifični spojevi formule I uključuju slijedeće spojeve:
2-cikloheksil-N-hidroksi-2-[{3-[4-(2-hidroksietil)piperidin-1-il]-3-oksopropil}-(4-metoksibenzensulfonil)amino] acetamid;
N-hidroksi-2-[{3-[5-(2-hidroksietil)-2,5-diazabiciklo[2.2.1]-hept-2-il]-3-oksopropil}-(4-metoksi-benzensulfonil) amino]-3-metilbutiramid;
2-{(4-benziloksibenzensulfonil)-[3-(4-hidroksipiperidin-1-il)-3-oksopropil]amino}-N-hidroksi-3-metilbutiramid;
2-cikloheksil-2-{[4-(4-fluorofenoksi)benzensulfonil]-[3-(4-hidroksi-piperidin-1-il)-3-oksopropil]-amino}-N-hidroksiacetamid;
2-{[4-(4-butilfenoksi)benzensulfonil]-[3-(4-hidroksipiperidin-1-il)-3-oksopropil]-amino}-N-hidroksi-3-metilbutiramid;
hidroksamid 1-{(4-metoksibenzensulfonil)-[3-(4-metilaminopiperidin-1il)-3-okso-propil]amino}-ciklopentankarboksilne kiseline;
etil estar 4-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzen-sulfonil)amino]-propionil}piperazin-2-karboksilne kiseline;
etoksikarboniloksimetil estar 3-[(cikloheksil-hidroksikarbamoil-metil)-(4-metoksi-benzen-sulfonil)amino] propionske kiseline;
etoksikarboniloksimetil estar 3-[(1-hidroksikarbamoilpentil)-(4-metoksi-benzensulfonil)amino]propionske kiseline;
etoksikarboniloksimetil estar 3-[[4-(4-fluorobenziloksi)-benzensulfonil]-(1-hidroksi-karbamoil-2-metil-propil)-amino]-propionske kiseline; i
etoksikarboniloksimetil estar 3-[[4-(4-fluorofenoksi)-benzensulfonil]-(1-hidroksi-karbamoil-2-metil-propil)-amino]-propionske kiseline.
Opisani izum također se odnosi na farmaceutski preparat za: (a) tretiranje stanja odabranog iz grupe koju čine artritis, karcinom, sinergija sa citotoksičnim antikarcinomnim agensima, ulcer tkiva, makularna degeneracija, restenozis, periodontalno oboljenje, epidermolizis bulosa, skleritis, u kombinaciji sa standardnim NSAID'S i analgeticama, i druga oboljenja koja su karaketrizirana sa aktivnošću matrične metaloproteinaze, AIDS, sepsa, sepstični šok i druga oboljenja koja obuhvaćaju proizvodnju faktora tumorne nekroze (TNF); ili (b) inhibiciju matričnih metaloproteinaza ili proizvodnje faktora tumorne nekroze (TNF) kod sisavaca, uključujući i ljude, koji obuhvaća takvu količinu spoja formule I ili njegove farmaceutski prihvatljive soli, koja je efikasna u takvim tretmanima i farmaceutski prihvatljiv nosač.
Opisani izum se također odnosi na postupak za inhibiciju: (a) matričnih metaloproteinaza; ili (b) inhibiciju proizvodnje faktora tumorne nekroze (TNF) kod sisavaca, uključujući i ljude, koji obuhvaća primjenu kod spomenutih sisavaca efikasne količine spoja formule I ili njegove farmaceutski prihvatljive soli.
Opisani izum se također odnosi na postupak za tretiranje stanja odabranog iz grupe koju čine artritis, karcinom, ulcer tkiva, makularna degeneracija, restenozis, periodontalno oboljenje, epidermolizis bulosa, skleritis. Spojevi formule I mogu se koristiti u kombinaciji sa standardnim NSAID'S i analgeticima, te u kombinaciji sa citotoksičnim antikarcinomnim agensima, i za druga oboljenja koja su karaketrizirana sa aktivnošću matrične metaloproteinaze, AIDS, sepsis, sepstični šok i druga oboljenja koja obuhvaćaju proizvodnju faktora tumorne nekroze (TNF) kod sisavaca, uključujući i ljude, koji obuhvaća primjenu kod spomenutih sisavaca takve količine spoja formule I ili njegove farmaceutski prihvatljive soli, koja je efikasna u tretiranju takvog stanja.
Detaljni opis izuma
Slijedeće reakcijske sheme ilustriraju dobivanje spojeva opisanog izuma. Ako nije drugačije naglašeno, n, R3, R4, X i Ar u reakcijskim shemama i diskusiji koja sledi su kako je definirano naprijed.
[image]
[image]
U reakcijskoj shemi 1, amino kiselinski spoj formule VII, gdje R16 je (C1-C6) alkil, benzil, alil ili terc-butil, prevodi se u odgovarajući spoj formule VI reakcijom spoja VII sa reaktivnim funkcionalnim derivatom arilsulfonske kiseline, takvim kao što je arilsulfonil klorid, u prisustvu baze, takve kao što je trietilamin, i polarnog otapala, takvog kao što je tetrahidrofuran, dioksan, voda ili aecetonitril, poželjno smjesa dioksana i vode. Reakcijska smjesa se miješa, na sobnoj temperaturi, tokom vremenskog perioda između oko 10 minuta do oko 24 sata, poželjno oko 60 minuta.
U reakciji 2 sheme 1, arilsulfonil amino spoj formule VI, gdje R16 je (C1-C6) alkil, benzil, alil ili terc-butil, prevodi se u odgovarajući spoj formule V, gdje n je 1,3,4,5 ili 6, reagiranjem spoja formule VI sa reaktivnim derivatom alkohola formule
[image]
takvim kao što je klorid, bromid ili jodid derivat, poželjno jodid derivat, gdje R17 zaštitna grupa je (C1-C6) alkil, benzil, alil ili terc-butil, u prisustvu baze takve kao što je kalij karbonat ili natrij hidrid, poželjno natrij hidrad, i polarnog otapala, takvog kao što je dimetilformamid. Reakcijska smjesa se miješa na sobnoj temperaturi, tokom vremenskog perioda između 60 minuta do oko 48 sati, poželjno oko 18 sati. R17 zaštitna grupa bira se tako da se može selektivno ukloniti u prisustvu i bez gubitka R16 zaštitne grupe, stoga R17 ne može biti isto kao R17. Uklanjanje R17 zaštitne grupe iz spoja formule V radi dobivanja odgovarajuće karboksilne kiseline formule IV, u reakciji 3 sheme 1, izvodi se pod uvjetima koji su odgovarajući za određenu R17 zaštitnu grupu u primjeni koja neće utjecati na R16 zaštitnu grupu. Takvi uvjeti uključuju: (a) saponifikaciju, gdje R17 je (C1-C6)alkil i R16 je terc-butil; (b) hidrogenolizu, gdje je R17 je benzil, a R16 je terc-butil ili (C1-C6)alkil; (c) tretiranje sa jakom kiselinom, takvom kao što je trifluorooctena kiselina ili klorovodična kiselina, gdje je R17 terc-butil, a R16 je (C1-C6)alkil, benzil ili alil; ili (d) tretiranje sa tributilkalaj-hidridom i octenom kiselinom u prisustvu katalitičkog bis(trifenilfosfin) paladij (II) klorida, gdje je R17 alil, a R16 je (C1-C6)alkil, benzil ili terc-butil.
U reakciji 4 sheme 1, karboksilna kiselina formule IV kondenzira se sa spojem HX ili sa njegovom solju, gdje je X kako je definirano naprijed, radi dobivanja odgovarajućeg amidnog spoja formule III. Formiranje amida iz primarnih ili sekundarnih amina ili amonijaka i karboksilnih kiselina ostvaruje se pomoću konverzije karboksilne kiseline u aktivni funkcionalni derivat, koji se zatim podvrgava reakciji sa primarnim ili sekundarnim aminom ili amonijakom radi formiranja amida. Aktivni funkcionalni derivat može se izolirati prije reakcije sa primarnim ili sekundarnim aminom ili amonijakom. Alternativno, karboksilna kiselina može se tretirati sa oksalil kloridom ili tionil kloridom, bez ili u inertnom otapalu, takvom kao što je kloroform, na temperaturi između oko 25 °C do oko 80 °C, poželjno oko 50 °C, radi dobivanja odgovarajućeg klorida kiseline kao funkcionalnog derivata. Inertno otapalo i nešto zaostalog oksalil klorida ili tionil klorida, tada se uklanja pomoću isparavanja pod vakuumom. Zaostali klorid kiseline kao funkcionalni derivat tada reagira sa primarnim ili sekundarnim aminom ili amonijakom u inertnom otapalu, takvom kao što je metilen klorid, radi formiranja amida. Poželjni postupak za kondenezaciju karboksilne kiseline formule IV sa spojem formule HX, gdje je X kako je definirano naprijed, radi dobivanja odgovarajućeg spoja formule III, je tretiranje spoja formule IV sa (benzotriazol-1-iloksi)tris-(dimetilamino)fosfonij heksafluorofosfatom u prisustvu baze, takve kao što je trietilamin, radi dobivanja benzotriazol-1-oksi estra in situ koji reagira sa spojem formule HX, u inertnom otapalu, takvom kao što je metilen klorid, na sobnoj temperaturi radi dobivanja spoja formule III.
Uklanjanje R16 zaštitne grupe iz spoja formule III radi dobivanja odgovarajuće karboksilne kiseline formule II, u reakciji 5 sheme 1, vrši se pod uvjetima koji su odgovarajući za određenu R16 grupu koja se koristi. Takvi uvjeti uključuju: (a) saponifikaciju, gdje je R16 niži alkil; (b) hidrogenolizu, gdje je R16 benzil; (c) tretiranje sa jakom kiselinom, takvom kao što je trifluorooctena kiselina ili klorovodična kiselina, gdje je R16 terc-butil; ili (d) tretiranje sa tributilkalaj-hidridom i octenom kiselinom u prisustvu katalitičkog bis(trifenilfosfin) paladij (II) klorida, gdje je R16 alil.
U reakciji 6 sheme 1, karboksilna kiselina spoja formule II prevodi se u hidroksaminsku kiselinu spoja formule I, tretiranjem spoja formule II sa 1-(3-dimetilaminopropil)-3-etilkarbodiimidom i 1-hidroksibenzitriazolom u polarnom otapalu, takvom kao što je dimetilformamid, što je praćeno dodavanjem hidroksilamina u reakcijsku smjesu poslije vremenskog perioda između oko 15 minuta do oko 1 sata, poželjno oko 30 minuta. Hidroksilamin se poželjno formira in situ iz oblika soli, takve kao što je hidroksilamin hidroklorid, u prisustvu baze, takve kao što je N-metilmorfolin. Alternativno, zaštićen derivat hidroksil-amina ili njegovog oblika soli, gdje je hidroksi grupa zaštićena kao terc-butil, benzil, alil ili trimetilsililetar, može se koristiti u prisustvu (benzotriazol-1-iloksi)-tris(dimetilamino) fosfonij heksafluorofosfata i baze, takve kao što je N-metilmorfolin. Uklanjanje hidroksilamin zaštitne grupe vrši se pomoću hidrogenolize za benzil zaštitnu grupu ili tretiranja sa jakom kiselinom, takvom kao što je trifluorooctena kiselina, za terc-butil zaštitnu grupu. Alil zaštitna grupa može se ukloniti pomoću tretiranja sa tributilkalaj-hidridom i octenom kiselinom u prisustvu katalitičkog bis(trifenilfosfin) paladij (II) klorida. 2-trimetilsililetil etar može se ukloniti pomoću reakcije sa jakom kiselinom, takvom kao što je trifluorooctena kiselina ili pomoću reakcije sa izvorom fluorida, takvim kao što je bor trifluorid eterat. N,O-bis(4-metoksibenzil) hidroksilamin može se također koristiti kao zaštićen hidroksilamin derivat, gdje se uklanjanje zaštite vrši uz korištenje smjese metansulfonske kiseline i trifluorooctene kiseline.
U reakciji 1 sheme 2, arilsulfonilamino spoj formule VI, gdje R16 je (C1-C6) alkil, benzil ili terc-butil prevodi se u odgovarajući spoj formule VIII reakcijom spoja formule VI sa reaktivnim funkcionalnim derivatom, takvim kao što je halid, poželjno jodid derivat 3-(terc-butildimetilsililoksi)-1-propanola u prisustvu baze, takve kao što je natrij hidrid. Reakcija se vrši u polarnom otapalu, takvom kao što je dimetilformamid, na sobnoj temperaturi, tokom vremenskog perioda između oko 2 sata i oko 48 sati, poželjno oko 18 sati.
U reakciji 2 sheme 2, spoj formule VIII prevodi se u alkohol spoja formule IX, tretiranjem spoja formule VIII sa viškom kiseline, takve kao što je octena kiselina, ili viškom Lewis-ove kiseline, takve kao što je bor trifluorid eterat. Kada se koristi kiselina, takva kao što je octena kiselina, dodaje se voda, a vodeno-topljivo ko-otapalo, takavo kao što je tetrahidrofuran može se dodati radi poboljšanja topljivosti. Reakcija se miješa tokom vremenskog perioda između oko 18 sati i oko 72 sata, poželjno oko 24 sata, na temperaturi između oko sobne temperature do oko 60 °C, poželjno oko 50 °C. Kada se koristi Lewis-ova kiselina, takva kao što je bor trifluorid eterat, reakcija se miješa u otapalu, takvom kao što je metilen klorid, tokom vremenskog perioda između oko 10 minuta do oko 6 sati, poželjno oko 20 minuta, na temperaturi između oko -20 °C do oko sobne temperature, poželjno oko sobne temperature.
U reakciji 3 sheme 2, alkohol spoja formule IX oksidira se do karboksilne kiseline spoja formule IV, gdje n je 2, pomoću reagiranja spoja formule IX sa viškom natrij perijodata i katalitičke količine rutenij triklorida u smjesi otapala koju čine acetonitril, voda i ugljik tetraklorid, na sobnoj temperaturi, tokom vremenskog perioda između oko 1 sat do oko 24 sata, poželjno oko 4 sata.
Spoj formule IV, gdje n je 2, dalje reagira radi dobivanja hidroksamske kiseline spoja formule I, gdje n je 2, prema proceduri opisanoj naprijed u reakcijama 4, 5 i 6 sheme 1.
Farmaceutski prihvatljive soli kiselinskih spojeva izuma su soli izgrađene sa bazama, tj. kationske soli takve kao što su soli alkalnih i zemno alkalnih metala, takvih kao što su natrij, litij, kalij, kalcij, magnezij, kao i amonijeve soli, takve kao što su amonij trimetil-amonij dietilamonij i tris-(hidroksimetil)-metilamonij soli.
Slično, za kiselinske adicijske soli, takve kao što su soli mineralnih kiselina, organskih karboksilnih i organskih sulfonskih kiselina, npr. klorovodična kiselina, metansulfonska kiselina, maleinska kiselina, također je moguće da sadrže i baznu grupu, takvu kao što je piridil, koja čini dio njihove strukture.
Sposobnost spojeva formule I ili njihovih farmaceutski prihvatljivih soli (ovdje kasnije također označeni kao “spojevi opisanog izuma”) za inhibiranje matričnih metaloproteinaza ili proizvodnju faktora tumorne nekroze (TNF) i stoga pokazivanje njihove efikasnosti za tretiranje oboljenja karakteriziranih pomoću matričnih metaloproteinaza ili faktora tumorne nekroze pokazana je prateći in vitro testne pokuse.
BIOLOŠKO ISPITIVANJE
Inhibicija ljudske kolagenaze (MMP-1)
Ljudska rekombinantna kolagenaza aktivira se sa tripsinom, uz korištenje slijedećeg odnosa: 10 µg tripsina na 100 µg kolagenaze. Tripsin i kolagenaza inkubiraju se na sobnoj temperaturi tokom 10 minuta, i tada se doda peterostruki višak (50 µg/10 µg trispina) tripsinskog inhibitora soje.
10 mM otopine podloge inhibitora izgradi se u dimetil sulfoskidu i tada se razblaži uz korištenje slijedeće sheme:
10 mM → 120 µM → 12 µM → 1,2 µM → 0,12 µM
Dvadeset pet mikrolitara svake koncentracije, doda se tada u triplikatu u odgovarajuća okna mikrofluorne ploče od 96 okana. Konačna koncentracija inhibitora biti će 1 : 4 razblaženja poslije dodavanja enzima i supstrata. Pozitivne kontrole (enzim, bez inhibitora) postave se u okna D1 - D6, a slijepe probe (bez enzima, bez inhibitora) postave se u okna D7 - D12.
Kolagenaza se razblaži do 400 ng/ml, i tada se doda 25 µl u odgovarajuća okna mikrofluorne ploče. Konačna koncentracija kolagenaze u ispitiavnju je 100 ng/ml.
Supstrat (DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) napravi se kao 5 mM podloga u dimetil sulfoksidu, i tada se razblaži do 20 µM u spremniku za ispitivanje. Ispitivanje otpočinje pomoću dodavanja 50 µl supstrata po oknu mikrofluorne ploče radi dobivanja konačne koncentracije od 10 µM.
Očitavanja fluorescencije (360 nM ekscitacija, 460 nm emisija) vrše se u vremenu 0, a zatim na 20 minutnim intervalima. Ispitivanje se vrši na sobnoj temperaturi, obično sa vremenom trajanja ispitivanja od 3 sata.
Tada se prikaže fluorescencija prema vremenu za slijepe probe i uzorke koji sadrže kolagenazu (podaci iz triplikatnih određivanja uzimaju se kao prosječne vrijednosti). Vremenska točka koja daje dobar signal (slijepa proba) i ona na linearnom dijelu krivulje (obično na oko 120 minuta) odabrane su za određivanje IC50 vrijednosti. Vrijeme nula koristi se kao slijepa proba za svaki spoj na svakoj koncentraciji i ove vrijednosti se oduzimaju od podataka za 120 minuta. Podaci se prikazuju kao koncentracija inhibitora prema postotku kontrole (inhibitorska fluorescencija podijeljena sa fluorescencijom same kolagenaze × 100). IC50 vrijednosti određuju se iz koncentracije inhibitora koja daje signal koji je 50 % kontrolnog.
Ako se pokaže da su IC50 vrijednosti manje od 0,03 µM, tada se inhibitori ispituju pri koncentracijama od 0,3 µM, 0,03 µM i 0,003 µM.
Inhibicija želatinaze (MMP-2)
Inhibicija želatinazne aktivnosti vrši se uz korištenje Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2 supstrata (10 µM), pod istim uvjetima kao inhibicija ljudske kolagenaze (MMP-1).
72 kD želatinaze aktivira se sa 1 mM APMA (p-aminofenil merkuri acetat) tokom 15 sati na 4 °C i razblaži se radi dobivanja konačne koncentracije pri ispitivanju od 100 mg/ml. Inhibitori se razblaže kao za inhibiciju ljudske kolagenaze (MMP-1) radi dobivanja konačnih koncentracija u ispitivanju od 30 µM, 3 µM, 0,3 µM i 0,03 µM. Svaka koncentracija se koristi u triplikatu.
Očitavanja fluorescencije (360 nm ekscitacija, 460 nm emisija) vrše se u vremenu 0, a zatim na 20 minutnim intervalima tokom 4 sata.
IC50 vrijednosti određuju se kao za inhibiciju ljudske kolagenaze (MMP-1). Ako se pokaže da su IC50 vrijednosti manje od 0,03 µM, tada se inhibitori ispituju pri koncentracijama od 0,3 µM, 0,03 µM i 0,003 µM.
Inhibicija stromelizinske aktivnosti (MMP-3)
Inhibicija stromelizinske aktivnosti bazirana je na modificiranom spektrofotometrijskom ispitivanju koje su opisali Weingarten H. i Feder J., Spectrophotometric Assay for Vertebrate Collagenase, Anal. Biochem., 147, 437 - 440, 1985. Hidroliza tio peptolidnoog supstrata [Ac-Pro-Leu-Gly-SCH[CH2CH(CH3)2]CO-Leu-Gly-OC2H5] daje merkaptanski fragment koji može biti praćen u prisustvu Ellman-ovog reagensa.
Ljudski rekombinantni prostromelizin aktivira se sa tripsinom uz korištenje slijedećeg odnosa: 1 µg 10 mg/ml tripsinske podloge na 26 µg stromelizina. Tripsin i stromelizin inkubiraju se na 37 °C tokom 15 minuta što je praćeno inkubiranjem 10 µl 10 mg/ml tripsinskog inhibitora tokom 10 minuta na 37 °C radi zaustavljanja tripsinske aktivnosti.
Ispitivanja se vrše u ukupnom volumenu od 250 µl spremnika za ispitivanje (200 mM natrij klorida, 50 mM MES i 10 mM kalcij klorida, pH 6,0) u mikrolitarskim pločama sa 96 okana. Aktivirani stromelizin razblaži se u spremniku za ispitivanje do 25 µg/ml. Ellman-ov reagens (3-karboksi-4-nitrofenil disulfid) napravi se kao 1M podloga u dimetil formamidu i razblaži se do 5 mM u spremniku za ispitivanje sa 50 µl po oknu radi dobivanja 1 mM konačne koncentracije.
10 mM otopine podloge izgradi se u dimetil sulfoksidu i serijski se razblaži u spremniku za ispitivanje tako da dodavanje 50 µL u odgovarajuća okna daje konačne koncentracije od 0,3 µM, 0,3 µM, 0,003 µM i 0,0003 µM. Sve se radi u triplikatu.
300 mM dimetil sulfoksidni otopina podloge peptidnog supstarta razblaži se do 15 mM u spremniku za ispitivanje i ispitivanje počinje sa dodavanjem 50 µl u svako okno radi postizanja konačne koncentracije od 3 mM supstrata. Slijepe probe sadrže peptidni supstrat i Ellman-ovu otopinu bez enzima. Formiranje proizvoda prati se na 405 nm sa Molecular Devices UVmax čitačem ploča.
IC50 vrijednosti određuju se na isti način kao za kolagenazu.
Inhibicija MMP-13
Ljudski rekombinantni MMP-13 aktivira se sa 2mM APMA-om (p-aminofenil merkuri acetat) tokom 1,5 sata na 37 °C i razblaži se do 400 mg/ml u spremniku za ispitivanje (50 mM Tris, pH 7,5, 200 mM natrij klorid, 5 mM kalicij klorid, 20 µM cink klorid, 0,02 % brij-a). Dvadeset-pet mikrolitara razblaženog enzima doda se po oknu 96 mikrofluorne ploče. Enzim se tada razblaži u odnosu 1 : 4 u pokusu pomoću dodavanja inhibitora i supstrata radi dobivanja konačne koncentracije za ispitivanje od 100 mg/ml.
10 mM otopine podloge inhibitora izgradi se u dimetil sulfoksidu, i tada se razblaži u spremniku za ispitivanje kao po navedenoj shemi za razblaživanje inhibitora za inhibiciju ljudske kolagenaze (MMP-1). Dvadeset pet mikrolitara svake koncentracije doda se u triplikatu na mikrofluornu ploču. Konačne koncentracije pri ispitivanju su 30 µM, 3µM, 0,3 µM i 0,03 µM.
Supstrat (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) pripremi se kao za inhibiciju ljudske kolagenaze (MMP-1), i svakom oknu doda se 50 µl radi dobivanja konačne koncentracije za ispitivanje od 10 µM. Očitavanja fluorescencije (360 nM ekscitacija; 450 nm emisija) tada se vrše u vremenu 0, a zatim na svakih 5 minuta tokom 1 sata.
Pozitivne kontrole sadrže enzim i supstrat bez inhibitora, a slijepe probe sadrže samo supstrat.
IC50 vrijednosti određuju se kao za inhibiciju ljudske kolagenaze (MMP-1). Ako se pokaže da su IC50 vrijednosti manje od 0,03 µM, tada se inhibitori ispituju pri koncentracijama od 0,3 µM, 0,03 µM, 003 µM i 0,0003 µM.
Inhibicija proizvodnje TNF
Sposobnost spojeva ili njegovih farmaceutski prihvatljivih soli da inhibiraju proizvodnju TNF, i stoga pokazivanje njihove efikasnosti za tretiranje oboljenja koja obuhvaćaju proizvodnju TNF, pokazana je pomoću slijedećeg in vitro ispitivanja.
Ljudske mononuklearne stanice izoliraju se iz anti-koagulirane ljudske krvi uz korištenje jednostupanjske Ficoll-hypaque tehnike. (2) Ljudske mononuklearne stanice isperu se tri puta u Hanks-ovoj ravnotežnoj otopini soli (HBSS) sa dvovalentnim kationima, i resuspendiraju se do gustoće od 2 × 106 stanica/ml u HBSS koji sadrži 1 % BSA. Diferencijalne vrijednosti određuju se korištenjem Abbot Cell Dyn 3500 analizatora. Na ovaj način pokazano je da monociti čine od 17 do 24 % svih stanica u ovim preparatima.
180 µl stanične suspenzije izdvoji se na ravno dno ploča sa 96 okana (Costar). Dodavanja spojeva i LPS (100 ng/ml konačne koncentracije) daje konačni volumen od 200 µl. Sve se ponavlja u triplikatu. Poslije 4 sata inkubacije na 37 °C u vlažnom CO2 inkubatoru, ploče se uklone i centrifugiraju (10 minuta na oko 250 × g), a supernatanti se uklone i ispituju na TNF� korištenjem opreme R&D ELISA Kit.
Za primjenu kod sisavaca, uključujući i ljude, za inhibiciju matričnih metaloproteinaza ili inhibiciju proizvodnje faktora tumorne nekroze (TNF), mogu se koristiti razni uobičajeni načini primjene uključujući oralni, parenteralni i topikalni. Općenito, aktivni spoj biti će primjenjivan oralno i pareneteralno pri dozama između oko 0,1 i 25 mg/kg tjelesne mase subjekta koji se tretira na dan, poželjno od oko 0,3 do 5 mg/kg. Međutim, izvjesno variranje u dozi biti će potrebno izvesti zavisno od stanja subjekta koji se tretira. Osoba odgovorna za primjenu, u svakom će slučaju odrediti odgovarajuću dozu za svaki individualni subjekt.
Spojevi opisanog izuma mogu se primjenjivati u velikom mnoštvu različitih doznih oblika. Općenito, terapeutski efikasni spojevi ovog izuma su prisutni u takvim doznim oblicima pri koncentracijskim nivoima koji idu od oko 5,0 do oko 70 masenih postotaka.
Za oralnu primjenu, tablete koje sadrže različite ekscipijente, takve kao što su mikrokristalna celuloza, natrij citrat, kalcij karbonat, dikalcij fosfat i glicin mogu se koristiti zajedno sa različitim dizintegrantima, takvim kao što su škrob (poželjno škrob kukuruza, krumpira ili tapioke), alginska kiselina i izvjesni kompleksni silikati, zajedno sa granulacijskim vezivima takvim kao što su polivinilpirolidon, saharoza, želatina i akacija. Dodatno agensi za podmazivanje, takvi kao što su magnezij stearat, natrij lauril sulfat i talk, često su vrlo korisni za svrhe tabletiranja.
Čvrsti preparati sličnog tipa mogu se također koristiti kao punila u želatinskim kapsulama; poželjni materijali u vezi sa ovim također uključuju laktozu ili mliječni šećer, isto kao i polietilen glikole visoke molekulske mase. Kada se žele vodene suspenzije i/ili eliksiri za oralnu primjenu, aktivni sastojak može biti sjedinjen sa različitim agensima za ukus ili zaslađivanje, sa obojenim materijama ili bojama i, ako se želi, emulgirajućim i/ili suspendirajućim agensima, zajedno sa takvim razblaživačima, kao što su voda, etanol, propilen glikol, glicerin i njihove različite kombinacije. U slučaju primjene kod životinja, prikladno je da budu sadržani u hrani za životinje ili pijućoj vodi u koncentraciji od 5 do 5000 ppm, poželjno 25 do 500 ppm.
Za parenteralnu primjenu, npr. za intramuskularno, intraperitonelno, potkožno i intarvensko korištenje, obično se priprema sterilni injektibilna otopina aktivnog sastojka. Otopine terapeutskog spoja opisanog izuma, bilo u sezamovom, bilo u ulju kikirikija ili vodenom propilen glikolu, mogu se koristiti. Vodene otopine trebaju biti prikladno podešeni i pohranjeni, poželjno na pH vrijednost veću od 8, i ako je potrebno tekući razblaživač prvo treba osigurati izotoničnost sa krvlju ovih otopina. Ove vodene otopine prikladne su za svrhe intravenskog injektiranja. Uljne otopine prikladne su za svrhe intrazglobnog, intarmuskularnog i potkožnog injektiranja. Dobivanje svih ovih otopina pod sterilnim uvjetima lako se postiže pomoću standardnih farmaceutskih tehnika, koje su dobro poznate stručnjacima u ovoj oblasti tehnike. U slučaju životinja, spojevi se mogu primjenjivati intramuskularno ili potkožno pri doznim nivoima od oko 0,1 do 50 mg/kg/dan, prikladno od 0,2 do 10 mg/kg/dan u jednoj dozi ili izdijeljeno u do tri doze na dan.
Opisani je izum ilustriran pomoću slijedećih primjera, ali nije ograničen na njihove detalje.
Primjer 1
2-cikloheksil-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-aminopiperidin-1-il)-3-oksopropil]amino} acetamid
A) Otopini hidroklorida benzil estra D-cikloheksilglicina (17,0 grama, 59,9 mmola) i trietilamina (17,6 ml, 126,3 mmola) u vodi (60 ml) i 1,4-dioksanu (100 ml) doda se 4-metoksibenzensulfonil klorid (13,0 grama, 62,9 mmola). Smjesa se miješa na sobnoj temperaturi tokom 16 sati i tada se glavnina otapala ukloni isparavanjem pod vakuumom. Smjesa se razblaži sa etil acetatom i ispere uzastopno sa razblaženom otopinom klorovodične kiseline, zasićenom otopinom natrij bikarbonata i slanom otopinom. Organska otopina osuši se iznad magnezij sulfata i koncentrira radi dobivanja benzil estra N-(4-metoksibenzensulofonil)-D-cikloheksilglicina u obliku bijele čvrste supstance, 24,51 grama (99 %).
B) Benzil estar N-(4-metoksibenzensulofonil)-D-cikloheksilglicin (12,0 grama, 29,16 mmola) doda se suspenziji natrij hidrida (0,78 grama, 32,5 mmola) u suhom N,N-dimetilformamidu (100 ml), a poslije 20 minuta doda se terc-butil-(3-jodopropoksi)-dimetilsilan (9,2 grama, 30,6 mmola). Dobivena se smjesa miješa na sobnoj temperaturi tokom 16 sati i tada se reakcija zaustavlja dodatkom zasićeneg otopine amonij klorida. Tada se N,N-dimetilformamid ukloni isparavanjem pod vakuumom. Ostatak se uzme u dietil etar i ispere uzastopno sa razblaženom otopinom klorovodične kiseline, vodom i slanom otopinom. Poslije sušenja iznad magnezij sulfata, dietil etar se ispari pod vakuumom radi dobivanja žutog ulja iz koga se izdvaja benzil estar [[3-(terc-butildimetilsilaniloksi)propil](4-metoksi-benzensulfonil)-amino]cikloheksiloctene kiseline u obliku bistrog ulja (13,67 grama, 79 %) pomoću pulsne kromatografije na silikagelu uz eluiranje sa 10 % etil acetatom u heksanu.
C) Otopini benzil estra [[3-(terc-butildimetilsilaniloksi)propil](4-metoksi-benzensulfonil)-amino]cikloheksil octene kiseline (13,67 grama, 23,2 mmola) u metilen kloridu (60 ml), na sobnoj temperaturi, doda se bor trifluorid eterat (21 ml, 171 mmola). Poslije 20 minuta, reakcija se zaustavlja pomoću dodavanja zasićeneg otopine amonij klorida i uzastopnim dodavanjem etil acetata i vode. Organska faza se odvoji, ispere sa slanom otopinom i osuši iznad magnezij sulfata. Isparavanje otapala pod vakuumom daje ulje iz koga se izolira benzil estar cikloheksil[(3-hidroksipropil)(4-metoksi-benzensulfonil)amino]octene kiseline, u obliku bistrog ulja (11,25 grama, 100 %) pomoću pulsne kromatografije na silikagelu uz eluiranje sa 20 % etil acetatom u heksanu i zatim sa 40 % etil acetatom u heksanu.
D) Benzil estar cikloheksil[(3-hidroksipropil)(4-metoksi-benzensulfonil)amino]octene kiseline (45,8 grama, 96 mmola) i natrij perijodat (92,6 grama, 433 mmola) otope se u smjesi acetonitrila (345 ml), ugljik tetraklorida (345 ml) i vode (460 ml). Uz hlađenje sa ledenom kupkom tada se doda rutenij triklorid monohidrat (4,4 grama, 21 mmola). Dobivena smjesa mehanički se miješa uz hlađenje sa ledenom kupkom tokom 30 minuta. Kupka se ukloni i miješanje se nastavlja na sobnoj temperaturi tokom 4 sata. Reakcijska se smjesa razblaži sa etil acetatom i profiltrira kroz diatomatejsku zemlju. Organski se sloj odvoji i vodeni sloj se ekstrahira sa etil acetatom. Sjedinjeni organski slojevi isperu se sa vodom i zasićenom slanom otopinom. Poslije sušenja iznad magenzij sulfata, otapala se upare radi dobivanja tamnog ulja iz kojeg se izolira 3-[(benziloksikarbonilciklo-heksilmetil)(4-metoksi-benzensulfonil)amino]propionska kiselina u obliku bijele pjene (28,1 grama, 60 %) pomoću pulsne kromatografije na silikagelu, uz eluiranje sa kloroformom i 1 % metanolom u kloroformu.
E) Otopini 3-[(benziloksikarbonilciklo-heksilmetil)(4-metoksi-benzensulfonil)-amino]propionske kiseline (1,57 grama, 3,21 mmola) u metilen kloridu (45 ml) dodaju se uzastopno trietilamin (1,12 ml, 8,04 mmola), terc-butil estar metil-piperidin-4-il karbamske kiseline (0,89 grama, 4,15 mmola) i (benzotriazol-1-iloksi)tris (dimetilamino)-fosfonij heksafluoroborat (1,56 grama. 3,53 mmola). Dobivena smjesa miješa se tokom 16 sati na sobnoj temperaturi i tada se razblaži sa metilen kloridom. Otopina se ispere uzastopno sa 0,5 M otopinom klorovodične kiseline, zasićenom otopinom natrij bikarbonata i slanom otopinom. Otopina se osuši iznad magnezij sulfata i koncentrira radi dobivanja ulja koje se kromatografira na silikagelu koji se eluira sa 50 % etil acetatom u heksanu radi dobivanja benzil estra [{3-[4-(tercbutoksikarbonilmetilamino)piperidin-1-il]-3-oksopropil}(4-metoksi-benzensulfonil)-amino]cikloheskiloctene kiseline u obliku ulja (1,98 grama, 86 %).
F) Otopini benzil estra [{3-[4-(terc-butoksikarbonilmetilamino)piperidin-1-il]-3-okso-propil}(4-metoksi-benzensulfonil)-amino]cikloheskiloctene kiseline (1,89 grama, 2,76 mmola) se doda 10 % paladija na aktivnom ugljiku (0,32 grama). Smjesa se miješa pod tlakom vodika od 3,039 bara u Parr mućkalici tokom 2 sata. Katalizator se ukloni pomoću filtriranja kroz najlon (veličina pora 0,45 µm) i otapalo se ispari radi dobivanja [{3-[4-(terc-butoksikarbonilmetilamino)-piperidin-1-il]-3-okso-propil}(4-metoksi-benzensulfonil)-amino] cikloheskiloctene kiseline u obliku bijele pjene (1,65 grama, 100 %).
G) Otopini [{(3-[4-(terc-butoksikarbonilmetilamino)-piperidin-1-il]-3-okso-propil}(4-metoksi-benzensulfonil)-amino]cikloheskiloctene kiseline (1,65 grama, 2,76 mmola) u metilen kloridu (30 ml) dodaju se uzastopno O-benzilhidroksiamin hidroklorid (0,47 grama, 2,94 mmola), trietilamin (1,25 ml, 9,0 mmola) i (benzotriazol-1-iloksi)tris(dimetilamino)fosfonij heksafluoroborat (1,36 grama, 3,07 mmola). Dobivena smjesa miješa se tokom 24 sata na sobnoj temperaturi i koncentrira na vakuumu. Ostatak se uzme u etil acetat i ispere uzastopno sa 0,5 M otopinom klorovodične kiseline, vodom, zasićenom otopinom natrij bikarbonata i slanom otopinom. Otopina se osuši iznad magnezij sulfata i koncentrira radi dobivanja ulja, koje se kromatografira na silikagelu uz eluiranje sa 40 % heksanom u etil acetatu radi dobivanja terc-butil estra (1-{3-[(benziloksikarbamoilcikloheksilmetil)(4-metoksi-benzensulfonil)-amino]propionil}piperidin-4-il)metil karbamske kiseline u obliku bistrog ulja (1,86 grama, 96 %).
H) Otopini terc-butil estra (1-{3-[(benziloksikarbamoilcikloheksilmetil)(4-metoksi-benzensulfonil)-amino] propionil}piperidin-4-il)metilkarbamske kiseline (1,86 grama, 2,65 mmola) u metanolu (80 ml) doda se 5 % paladija na barij sulfatu (0,85 grama). Smjesa se miješa pod tlakom vodika od 3,039 bara u Parr mućkalici tokom 2,5 sata. Katalizator se ukloni pomoću filtriranja kroz najlon (veličina pora 0,45 mm) i otapalo se ispari radi dobivanja terc-butil estra (1-{3-[(cikloheksil-hidroksikarbamoilmetil)(4-metoksi-benzensulfonil)-amino] propionil}piperidin-4-il)metilkarbamske kiseline u obliku bijele pjene (1,53 grama, 95 %).
Spojevi iz naslova primjera 2 - 8 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-valina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 2
1-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksibenzensulfonil)-amino]propionil}piperidin-4-il estar octene kiseline
Spojen je sa piperidin-4-il estrom octene kiseline. MS: 500 (M+1).
Primjer 3
1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksibenzensulfonil)-amino]propionil}piperidin-4-il estar butirne kiseline
Spojen je sa piperidin-4-il estrom butirne kiseline. MS: 528 (M+1).
Primjer 4
1-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksibenzensulfonil)amino]propionil}piperidin-4-il estar benzoeve kiseline
Spojen je sa piperidin-4-il estrom benzoeve kiseline. MS: 562 (M+1).
Analiza za C27H35N3O8S•1,75 H2O Izračunato: C 54,67; H 6,54; N 7,08.
Nađeno: C 54,52; H 6,14; N 7,85.
Primjer 5
N-hidroksi-2-[[3-(4-hidroksipiperidin-1-il)-3-oksopropil]-(4-metoksi-benzensulfonil)amino]-3-metilbutiramid
Spojen je sa 4-hidroksipiperidinom MS: 458 (M+1).
Analiza za C20H31N3O7S•H2O Izračunato: C 50,51; H 6,99; N 8,84.
Nađeno: C 50,04; H 6,84; N 9,14.
Primjer 6
Terc-butil estar (1-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksi-benzensulfonil)-amino]-propionil}piperidin-4-il)metil karbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline.
Primjer 7
Etil estar 1-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksibenzen-sulfonil)-amino]-propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 513 (M+1).
Primjer 8
Etil estar (4-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksibenzen-sulfonil)-amino]-propionil}piperazin-1-il)-octene kiseline
Spojen je sa etil estrom piperazin-iloctene kiseline.
HRMS izračunato za C23H37N4S8S (M+1): 529,2332; nađeno 529,2366.
Spojevi iz naslova primjera 9 - 10 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-leucina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 9
Terc-butil estar (1-{3-[(1-hidroksikarbamoil-3-metilbutil)(4-metoksibenzen-sulfonil)-amino]-propionil}piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-ilkarbmske kiseline. MS: 585 (M+1).
Primjer 10
Etil estar 1-{3-[(1-hidroksikarbamoil-3-metilbutil)(4-metoksibenzen-sulfonil)-amino]-propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. Točka topljenja 78 - 80 °C. MS: 528 (M+1).
Spojevi iz naslova primjera 11 - 13 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-norleucina kao polaznog materijala u stupnju A i naznačenog amina ili alkohola u stupnju E.
Primjer 11
Terc-butil estar (1-{3-[(1-hidroksikarbamoilpentil)(4-metoksibenzen-sulfonil)amino]-propionil}-piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline.
Primjer 12
Etil estar 1-{3-[(1-hidroksikarbamoilpentil)(4-metoksibenzen-sulfonil)amino]-propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil esterom piperidin-4-karboksilne kiseline. MS: 528 (M+1).
Primjer 13
Indan-5-il estar 3-[(1-hidroksikarbamoilpentil)(4-metoksibenzen-sulfonil)amino]-propionske kiseline
Spojen je sa 5-indanolom. MS: 505 (M+1).
Spojevi iz naslova primjera 14 - 15 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-terc-butilalanina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 14
Terc-butil estar (1-{3-[(1-hidroksikarbamoil-3,3-dimetilbutil)(4-metoksibenzen-sulfonil)-amino]propionil} piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline. MS: 599 (M+1).
Primjer 15
Etil estar 1-{3-[(1-hidroksikarbamoil-3,3-dimetilbutil)(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 542 (M+1).
Spojevi iz naslova primjera 16 - 18 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-cikloheksilglicina kao polaznog materijala u stupnju A i naznačenog amina ili alkohola u stupnju E.
Primjer 16
2-cikloheksil-N-hidroksi-2-[[3-(4-hidroksipiperidin-1-il)-3-oksopropil]-(4-metoksi-benzensulfonil)amino]acetamid
Spojen je sa 4-hidroskipiperidinom. MS: 498 (M+1).
Analiza za C23H35N3O7S•0,5H2O Izračunato: C 54,53; H 7,16; N 8,29.
Nađeno: C 54,21; H 6,98; N 8,21.
Primjer 17
Etil estar 1-{3-[(cikloheksilhidroksikarbamoilmetil)(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 554 (M+1).
Analiza za C26H39N3O8S•0,5H2O Izračunato: C 55,59; H 7,16; N 7,47.
Nađeno: C 55,53; H 7,18; N 7,57
Primjer 18
Indan-5-il estar 3-[(cikloheksilhidroksikarbamoilmetil)-(4-metoksibenzen-sulfonil)-amino]propionske kiseline
Spojen je sa 5-indanolom. MS: 531 (M+1).
Analiza za C27H34N2O7S•H2O Izračunato: C 59,11; H 6,61; N 5,10.
Nađeno: C 59,40; H 6,17; N 5,06.
Spojevi iz naslova primjera 19 - 20 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-fenilalanina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 19
Terc-butil estar (1-{3-[(1-hidroksikarbamoil-2-feniletil)(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline. MS: 619 (M+1).
Primjer 20
Etil estar 1-{3-[(1-hidroksikarbamoil-2-feniletil)-(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 561 (M+1).
Spojevi iz naslova primjera 21 - 22 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-4-fluorofenilalanina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 21
Terc-butil estar (1-{3-[[2-(4-fluorofenil)-1-hidroksikarbamoiletil]-(4-metoksibenzen-sulfonil)-amino]propionil} piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline.
Primjer 22
Etil estar 1-{3-[[2-(4-fluorofenil)-1-hidroksikarbamoiletil](4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 580 (M+1).
Analiza za C27H34FN3O8S Izračunato: C 55,95; H 5,91; N 7,25.
Nađeno: C 55,72; H 5,79; N 7,08.
Spojevi iz naslova primjera 23 - 24 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-4-homofenilalanina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 23
Terc-butil estar (1-{3-[(1-hidroksikarbamoil-3-fenilpropil)-(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline. MS: 633 (M+1).
Primjer 24
Etil estar 1-{3-[(1-hidroksikarbamoil-3-fenilpropil)-(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 576 (M+1).
Spojevi iz naslova primjera 25 - 26 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-O-terc-butilserina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 25
Terc-butil estar (1-{3-[(2-terc-butoksi-1-hidroksikarbamoiletil)(4-metoksibenzen-sulfonil)-amino]propionil} piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline. MS: 615 (M+1).
Primjer 26
Etil estar 1-{3-[(2-terc-butoksi-1-hidroksikarbamoiletil)(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 558 (M+1).
Spojevi iz naslova primjera 27 - 28 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-cikloheksilalanina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 27
Terc-butil estar (1-{3-[(2-cikloheksil-1-hidroksikarbamoiletil)-(4-metoksibenzen-sulfonil)-amino]propionil} piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline. MS: 625 (M+1).
Primjer 28
Etil estar 1-{3-[(2-cikloheksil-1-hidroksikarbamoiletil)(4-metoksibenzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 568 (M+1).
Spojevi iz naslova primjera 29 - 30 dobivaju se analogno kako je opisano u primjeru 1, uz korištenje benzil estra D-1-naftilalanina kao polaznog materijala u stupnju A i naznačenog amina u stupnju E.
Primjer 29
Terc-butil estar (1-{3-[(1-hidroksikarbamoil-2-naftalen-1-iletil)-(4-metoksibenzen-sulfonil)amino]propionil} piperidin-4-il)metilkarbamske kiseline
Spojen je sa terc-butil estrom metil-piperidin-4-il karbamske kiseline.
Primjer 30
Etil estar 1-{3-[(1-hidroksikarbamoil-2-naftalen-1-iletil)(4-metoksibenzen-sulfonil)amino]propionil}piperidin-4-karboksilne kiseline
Spojen je sa etil estrom piperidin-4-karboksilne kiseline. MS: 611 (M+1).
Primjer 31
2-cikloheksil-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-amino-piperidin-1-il)-3-oksopropil]-amino}acetamid
Otopina terc-butil estra 1-{3-[(cikloheksilhidroksikarbamoilmetil)(4-metoksi-benzensulfonil)-amino]-propionil} piperidin-4-il)metilkarbamske kiseline (1,53 grama, 2,50 mmola) u metilen kloridu (70 ml) se barbotira sa plinovitom klorovodičnom kiselinom tokom 2 minute. Kupka se ukloni i reakcijska smjesa se ostavi da se miješa na sobnoj temperaturi tokom 1 sata. Otapalo se ispari i ostatku se dva puta doda metanol i smjesa se ispari radi dobivanja 2-cikloheksil-N-hidroksi-2-{(4-metoksi-benzensulfonil)-[3-(4-metil-amino-piperidin-1-il)-3-oksopropil]-amino}acetamid hidroklorid dihidrata u obliku bijele čvrste supstance (1,22 grama, 90 %). MS: 511 (M+1).
Analiza za C24H39ClN4O6S•2H2O Izračunato: C 49,43; H 7,43; N 9,61.
Nađeno: C 49,86; H 7,23; N 9,69.
Spojevi iz naslova primjera 32 - 41 dobivaju se analogno kako je opisano u primjeru 33, uz korištenje naznačeneg polaznog materijala.
Primjer 32
N-hidroksi-2-{(4-metoksibenzensulfonil)[3-(4-metil-amino-piperidin-1-il)-3-oksopropil]amino}-3-metilbutiramid hidroklorid
Polazni materijal: terc-butil estar (1-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksibenzensulfonil)-amino] propionil}piperidin-4-il)-metilkarbamske kiseline uz korištenje terc-butil estra metil-piperidin-4-il karbamske kiseline. MS: 471 (M+1).
Primjer 33
Hidroksiamid hidroklorid 2-{(4-metoksibenzensulfonil)-[3-(4-metilamino-piperidin-1-il)-3-okso-propil]-amino}4-metilpentanoinske kiseline
Polazni materijal: terc-butil estar (1-{3-[(1-hidroksikarbamoil-3-metilbutil)(4-metoksibenzensulfonil)amino] propionil}piperidin-4-il)metilkarbamske kiseline. Točka topljenja 170 - 173 °C. MS: 485 (M+1).
Primjer 34
Hidroksiamid hidroklorid 2-{(4-metoksibenzensulfonil)-[3-(4-metilamino-piperidin-1-il)-3-okso-propil]amino} heksanoinske kiseline
Polazni materijal: terc-butil estar (1-{3-[(1-hidroksikarbamoil-pentil)-(4-metoksi-benzensulfonil)-amino]-propionil}piperidin-4-il)metil-karbamske kiseline. MS: 485 (M+1).
Analiza za C21H34N4O6S•HCl•4H2O Izračunato: C 43,50; H 7,48; N 9,67.
Nađeno: C 43,65; H 7,03; N 9,79.
Primjer 35
Hidroksiamid hidroklorid 2-{(4-metoksibenzensulfonil)-[3-(4-metilamino-piperidin-1-il)-3-okso-propil]amino}-4,4-dimetilpentanoinske kiseline
Polazni materijal: terc-butil estar (1-{3-[(1-hidroksi-karbamoil-3,3-dimetilbutil)(4-metoksi-benzensulfonil)amino] propionil}piperidin-4-il)metil-karbamske kiseline. MS: 499 (M+1).
Primjer 36
N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metilamino-piperidin-1-il)-3-oksopropil]amino}-3-fenilpropionamid hidroklorid
Polazni materijal: terc-butil estar (1-{3-(1-hidroksi-karbamoil-2-feniletil)(4-metoksi-benzensulfonil)-amino] propionil}piperidin-4-il)metil-karbamske kiseline. MS: 519 (M+1).
Primjer 37
3-(4-fluorofenil)-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metilamino-piperidin-1-il)-3-okso-propil]amino} propionamid hidroklorid
Polazni materijal: terc-butil estar (1-{3-[[2-(4-fluorofenil)-1-hidroksi-karbamoiletil]-(4-metoksi-benzensulfonil)-amino]propionil}-piperidin-4-il)metil-karbamske kiseline (primjer 21). MS: 537 (M+1).
Analiza za C25H33FN4O6S•HCl•2H2O Izračunato: C 49,30; H 6,29; N 9,20.
Nađeno: C 49,14; H 5,82; N 9,24.
Primjer 38
N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metilamino-piperidin-1-il)-3-oksopropil]amino}-4-fenilbutiramid hidroklorid
Polazni materijal: terc-butil estar (1-{3-[(1-hidroksi-karbamoil-3-fenilpropil)(4-metoksi-benzensulfonil)amino] propionil}piperidin-4-il)metil-karbamske kiseline Točka topljenja 160 - 170 °C. MS: 533 (M+1).
Analiza za C26H36N4O6S•HCl•1,5H2O Izračunato: C 52,38; H 6,76; N 9,40.
Nađeno: C 52,25; H 6,40; N 9,00.
Primjer 39
3-terc-butoksi-N-hidroksi-2-{(4-metoksibenzensulfonil)-3-(4-metil-amino-piperidin-1-il)-3-oksopropil]amino} propionamid hidroklorid
Polazni materijal: terc-butil estar (1-{3-[(2-terc-butoksi-1-hidroksi-karbamoiletil)-(4-metoksi-benzensulfonil) amino]propionil}piperidin-4-il)metil-karbamske kiseline MS: 515 (M+1).
Primjer 40
3-cikloheksil-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-amino-piperidin-1-il)-3-oksopropil]amino} propionamid hidroklorid
Polazni materijal: terc-butil estar (1-{3-[(2-cikloheksil-1-hidroksi-karbamoiletil)-(4-metoksi-benzensulfonil)amino] propionil}piperidin-4-il)metil-karbamske kiseline MS: 525 (M+1).
Primjer 41
N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-amino-piperidin-1-il)-3-oksopropil]amino}-3-naftalen-1-il-propionamid hidroklorid
Polazni materijal: terc-butil estar (1-{3-[(1-hidroksi-karbamoil-2-naftalen-1-iletil)-(4-metoksi-benzensulfonil) amino]propionil}piperidin-4-il)metil-karbamske kiseline MS: 569 (M+1).
Primjer 42
1-{3-[(cikloheksilhidroksikarbamoilmetil)(4-metoksibenzensulfonil)-amino]-propionil}piperidin-4-karboksilna kiselina
U otopinu etil estra 1-{3-[(cikloheksilhidroksikarbamoilmetil)(4-metoksi-benzensulfonil)-amino]propionil} piperidin-4-karboksilne kiseline (0,62 grama, 1,16 mmola) (primjer 17) u etanolu (45 ml) i vodi (5 ml) doda se litij hidroksid monohidrat (0,24 grama, 5,72 mmola). Poslije miješanja tokom 3 sata na sobnoj temperaturi dodaju se etanol,ispran sa Amberliti IR-120 i ionsko izmjenjivačka smola (6 grama). Miješanje se nastavlja tokom 15 minuta i smjesa se tada profiltrira. Filtrat se koncentrira na vakuumu radi dobivanja 1-{3-[(cikloheksilhidroksikarbamoil metil)(4-metoksibenzensulfonil)amino]propionil}-piperidin-4-karboksilne kiseline monohidrata u obliku bijele čvrste supstance (0,52 grama, 88 %). MS: 526 (M+1).
Analiza za C24H35N3O8S•H2O Izračunato: C 53,03; H 6,86; N 7,73.
Nađeno: C 53,53; H 7,15; N 7,70.
Spojevi iz naslova primjera 43 - 53 dobivaju se analogno kako je opisano u primjeru 45, uz korištenje naznačenog polaznog materijala.
Primjer 43
1-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksibenzen-sulfonil)amino]propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksi-benzensulfonil)amino] propionil}piperidin-4-karboksilne kiseline. MS: 486 (M+1).
Primjer 44
(4-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksibenzen-sulfonil)amino]propionil}piperazin-1-il)octena kiselina
Polazni materijal: etil estar (4-{3-[(1-hidroksikarbamoil-2-metilpropil)(4-metoksi-benzensulfonil)amino]-propionil}piperidin-1-il) octene kiseline (primjer 8). MS: 500 (M+1).
Primjer 45
1-{3-[(1-hidroksikarbamoil-3-metilbutil)(4-metoksibenzen-sulfonil)-amino]-propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(1-hidroksikarbamoil-3-metilbutil)(4-metoksi-benzensulfonil)-amino]propionil}piperidin-4-karboksilne kiseline. Točka topljenja 118 - 120 °C. MS: 500 (M+1).
Primjer 46
1-{3-[(1-hidroksikarbamoilpentil)(4-metoksibenzen-sulfonil)amino]-propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(1-hidroksikarbamoilpentil)(4-metoksi-benzensulfonil)-amino]propionil} piperidin-4-karboksilne kiseline. MS: 500 (M+1).
Primjer 47
1-{3-[(1-hidroksikarbamoil-3,3-dimetilbutil)(4-metoksi-benzen-sulfonil)-amino]propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(1-hidroksikarbamoil-3,3-dimetilbutil)(4-metoksi-benzensulfonil)-amino] propionil}piperidin-4-karboksilne kiseline. MS: 514 (M+1).
Primjer 48
1-{3-[(1-hidroksikarbamoil-2-feniletil)(4-metoksi-benzen-sulfonil)-amino]-propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(1-hidroksikarbamoil-2-fenil-etil)(4-metoksi-benzensulfonil)-amino]propionil} piperidin-4-karboksilne kiseline. MS: 534 (M+1).
Primjer 49
1-{3-[[2-(4-fluorofenil)-1-hidroksikarbamoiletil](4-metoksi-benzen-sulfonil)amino]propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[[2-(4-fluorofenil)-1-hidroksikarbamoiletil](4-metoksi-benzensulfonil)amino] propionil}piperidin-4-karboksilne kiseline. MS: 552 (M+1).
Analiza za C25H30FN3O8S•0,5H2O Izračunato: C 53,56; H 5,57; N 7,50.
Nađeno: C 53,53; H 5,39; N 7,28.
Primjer 50
1-{3-[(1-hidroksikarbamoil-3-fenilpropil)(4-metoksi-benzen-sulfonil)-amino]-propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(1-hidroksikarbamoil-3-fenil-propil)(4-metoksi-benzensulfonil)-amino]propionil} piperidin-4-karboksilne kiseline. Točka topljenja 85 - 92 °C. MS: 598 (M+1).
Primjer 51
1-{3-[(2-terc-butoksi-1-hidroksikarbamoil-etil)(4-metoksi-benzen-sulfonil)-amino]propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(2-terc-butoksi-1-hidroksikarbamoiletil)(4-metoksi-benzensulfonil)-amino] propionil}piperidin-4-karboksilne kiseline. MS: 529 (M+1).
Primjer 52
1-{3-[(2-cikloheksil-1-hidroksikarbamoil-etil)(4-metoksi-benzen-sulfonil)amino]propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(2-cikloheksil-1-hidroksikarbamoiletil)(4-metoksi-benzensulfonil) amino]propionil} piperidin-4-karboksilne kiseline. MS: 540 (M+1).
Primjer 53
1-{3-[(1-hidroksikarbamoil-2-naftalen-1-iletil)(4-metoksi-benzen-sulfonil)amino]propionil}piperidin-4-karboksilna kiselina
Polazni materijal: etil estar 1-{3-[(1-hidroksikarbamoil-2-naftalen-1-iletil)(4-metoksi-benzensulfonil)amino] propionil}piperidin-4-karboksilne kiseline. MS: 584 (M+1).
Primjer 54
N-hidroksi-2-[{3-[4-(2-hidroksietil)piperazin-1-il]-3-oksopropil}-(4-metoksi-benzen-sulfonil)amino]-3-metilbutiramid
A) U otopinu benzil estra 2-[(2-karoksietil)-(4-metoksi-benzensulfonil)amino]-3-metilbutirne kiseline (koji je dobiven polazeći od benzil estra D-valina prema proceduri iz primjera 1, stupnjevi A do D) (1,35 grama, 3,0 mmola) u metilen kloridu (45 ml) se uzastopno dodaju trietilamin (0,92 ml, 6,9 mmola), 2-piperazin-1-iletanol (0,43 grama, 3,3 mmola) i (benzotriazol-1-iloksi)tris-(dimetilamino)-fosfonij heksafluoroborat (1,53 grama, 3,45 mmola). Dobivena smjesa se miješa tokom 16 sati na sobnoj temperaturi i tada se koncentrira na vakuumu. Ostatak se uzme u etil acetat i ispere sa zasićenom otopinom natrij bikarbonata i slanom otopinom. Otopina se osuši iznad magnezij sulfata i koncentrira radi dobivanja ulja koje se kromatografira na silikagelu koji se eluira sa 5 % metanolom u kloroformu radi dobivanja benzil estra 2-[{3-[4-(2-hidroksietil)piperazin-1-il]-3-okso-propil}(4-metoksi-benzensulfonil)amino]-3-metilbutirne kiseline u obliku ulja (1,40 grama, 83 %). Prevođenje u hidrokloridnu sol uzastopno se izvodi uz korištenje anhidrirane klorovodične kiseline u hladnom (0 °C) metilen kloridu.
B) U otopinu hidroklorida benzil estra 2-[{3-[4-(2-hidroksietil)piperazin-1-il]-3-oksopropil}-(4-metoksi-benzensulfonil)amino]-3-metilbutirne kiseline (1,49 grama, 2,49 mmola) u etanolu (80 ml) doda se 10 % paladija na aktivnom ugljiku (0,11 grama). Smjesa se miješa pod tlakom vodika od 3,039 bara u Parr mućkalici tokom 16 sati. Katalizator se ukloni pomoću filtriranja kroz najlon (veličina pora 0,45 µm) i otopina se ispari radi dobivanja hidroklorida 2-[{3-[4-(2-hidroksietil)piperazin-1-il]-3-okso-propil}(4-metoksi-benzensulfonil) amino]-3-metilbutirne kiseline u obliku bijele čvrste supstance (1,16 grama, 92 %).
C) U otopinu hidroklorida 2-[{3-[4-(2-hidroksietil)piperazin-1-il]-3-okso-propil}(4-metoksi-benzensulfonil) amino]-3-metilbutirne kiseline (1,10 grama, 2,17 mmola) u metilen kloridu (50 ml) i N,N-dimetilformaidu (0,5 ml) dodaju se uzastopno O-benzilhidroksiamin hidroklorid (0,41 grama, 2,60 mmola), trietilamin (0,91 ml, 6,5 mmola) i (benzotriazol-1-iloksi)tris-(dimetilamino)-fosfonij heksafluoroborat (1,20 grama, 2,71 mmola). Dobivena smjesa se miješa tokom 16 sati na sobnoj temperaturi i tada se koncentrira na vakuumu. Ostatak se uzme u etil acetat i ispere uzastopno sa zasićenom otopinom natrij bikarbonata, vode i slanom otopinom. Otopina se osuši iznad magnezij sulfata i koncentrira radi dobivanja ulja koje se kromatografira na silikagelu i eluira sa 3 % metanolom u kloroformu radi dobivanja N-benziloksi-2-[{3-[4-(2-hidroksietil)piperazin-1-il]-3-oksopropil}(4-metoksi-benzensulfonil)amino]-3-metilbutiramida u obliku bistrog ulja (0,85 grama, 68 %). Prevođenje u hidrokloridnu sol se vrši uzastopno uz korištenje anhidrirane klorovodične kiseline u hladnom (0 °C) metilen kloridu.
D) U otopinu N-benziloksi-2-[{3-[4-(2-hidroksietil)piperazin-1-il]-3-oksopropil}-(4-metoksi-benzensulfonil) amino]-3-metilbutiramid hidroklorida (0,39 grama, 0,63 mmola) u metanolu (30 ml) doda se 5 % paladija na barij sulfatu (0,19 grama). Smjesa se miješa pod tlakom vodika od 3,039 bara u Parr mućkalici tokom 2,25 sata. Katalizator se ukloni pomoću filtriranja kroz najlon (veličina pora 0,45 µm) i otapalo se ispari radi dobivanja tamno žute pjene koja se kromatografira na silikagelu i eluira sa 15 % metanolom u kloroformu koji sadrži 0,5 % amonij hidroksida. Bistre frakcije koje sadrže željeni proizvod uzmu se u zasićenoj otopini natrij bikarbonata. Dobivena smjesa se ekstrahira više puta sa etil acetatom, a spojeni ekstrakti se koncentriraju radi dobivanja N-hidroksi-2-[{3-[4-(2-hidroksietil)-piperazin-1-il]-3-oksopropil}-(4-metoksi-benzensulfonil)amino] -3-metil-butiramida u obliku ulja. Hidrokloridna sol (0,20 grama, 61 %) formira se uz korištenje anhidrirane klorovodične kiseline u hladnom (0 °C) metanolu. MS: 487 (M+1).
Analiza za C21H34N4O7S•HCl•0,5H2O Izračunato: C 47,41; H 6,82; N 10,53.
Nađeno: C 47,41; H 7,11; N 9,91.
Spojevi iz naslova primjera 55 - 57 dobivaju se analogno kako je opisano u primjeru 58, uz korištenje naznačenog amina u stupnju A.
Primjer 55
2-[[3-(4-dimetilaminopiperidin-1-il)-3-oksopropil](4-metoksi-benzen-sulfonil)amino]-N-hidroksi-3-metilbutiramid
Spojen je sa dimetilpiperidin-4-ilaminom. MS: 485 (M+1).
Primjer 56
N-hidroksi-2-[{3-[4-(3-hidroksipropil)piperazin-1-il]-3-oksopropil}-(4-metoksi-benzen-sulfonil)amino]-3-metilbutiramid
Spojen je sa 3-piperazin-1-ilpropan-1-ol-om. MS: 500 (M+1).
Primjer 57
2-[(3-[1,4']bipiperidinil-1'-il-3-oksopropil)-(4-metoksi-benzen-sulfonil)-amino]-N-hidroksi-3-metilbutiramid
Spojen je sa korištenjem [1,4']bipiperidinila. MS: 525 (M+1).
Analiza C25H40N4O6S•HCl•1,5H2O Izračunato za: C 51,05; H 7,54; N 9,52.
Nađeno: C 50,80; H 7,45; N 9,36.
Primjer 58
Etil estar 1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-fenoksi-benzen-sulfonil)amino]propionil}piperidin-4-karboksilne kiseline
Spoj iz naslova se dobiva analogno kako je opisano u primjeru 1 uz korištenje benzil estra D-valina i 4-fenoksibenzensulfonil klorida kao polaznih materijala u stupnju A i etil estra piperidin-4-karboksilne kiseline u stupnju E.
Analiza za C28H37N3O8S•0,1CH2Cl2 Izračunato: C 57,78; H 6,42; N 7,19.
Nađeno: C 57,46; H 6,41; N 7,11.
Primjer 59
1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-fenoksi-benzen-sulfonil)amino]propionil}piperidin-4-karboksilna kiselina
Spoj iz naslova se dobiva analogno kako je opisano u primjeru 42 uz korištenje etil estra 1-{3-[(1-hidroksi karbamoil-2-metilpropil)-(4-fenoksi-benzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline (primjer 58) kao polaznog materijala. MS: 548 (M+1).
Analiza za C26H33N3O8S•0,5H2O Izračunato: C 56,10; H 6,16; N 7,75.
Nađeno: C 55,99; H 6,06; N 7,43.
Claims (10)
1. Spoj formule :
[image]
ili njegove farmaceutski prihvatljive soli, naznačen time što
n je 1 do 6;
X je OR1, gdje je R1 kako je definirano niže: azetidinil, pirolidinil, piperidinil, morfolinil, tiomorfolinil, indolinil, izoindolinil, tetrahidrohinolinil, tetrahidroizohinolinil, piperazinil ili premošten diazabicikloalkil prsten odabran iz grupe koju čine:
[image]
r je 1, 2 ili 3;
m je 1 ili 2; i
p je 0 ili 1;
gdje svaka heterociklična grupa može po izboru biti supstituirana sa jednom ili dvije grupe odabranih između hidroksi, (C1-C6)alkil, (C1-C6)alkoksi, (C1-C10)acil, (C1-C10)aciloksi, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkil, hidroksi (C1-C6)alkil, (C1-C6)alkoksi (C1-C6)alkil, (C1-C6)aciloksi (C1-C6)alkil, (C1-C6)alkiltio, (C1-C6)alkiltio (C1-C6)alkil, (C6-C10)ariltio, (C6-C10)ariltio (C1-C6)alkil, R9R10N, R9R10NSO2, R9R10NCO, R9R10NCO (C1-C6)alkil, gdje su R9 i R10 svaki nezavisno vodik, (C1-C6)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil ili (C5-C9)heteroaril (C1-C6)alkil ili R9 i R10 mogu zajedno sa atomom dušika na koji su spojeni formirati azetidinil, pirolidinil, piperidinil, morfolinil ili tiomorfolinil prsten; R12SO2, R12SO2NH, gdje je R12 trifluorometil, (C1-C6)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil ili (C5-C9)heteroaril (C1-C6)alkil; R13CONR9, gdje je R9 kako je definirano naprijed, a R13 je vodik, (C1-C6)alkil, (C1-C6)alkoksi, (C6-C10)aril, (C5-C9)heteroaril, (C1-C6)aril (C1-C6)alkil (C6-C10)aril (C1-C6)alkoksi ili (C5-C9)heteroaril (C1-C6)alkil; R14OOC, R14OOC (C1-C6)alkil, gdje R14 je (C1-C6)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, 5-indanil, CHR5OCOR6, gdje je R15 vodik ili (C1-C6)alkil i R6 je (C1-C6)alkil, (C1-C6)alkoksi ili (C6-C10)aril; CH2CONR7R8, gdje su R7 i R8 svaki nezavisno vodik, (C1-C6)alkil ili mogu zajedno sa atomom dušika na koji su vezani formirati azetidinil, pirolidinil, piperidinil, morfolinil ili tiomorfolinil prsten; ili R15O(C1-C6) alkil, gdje R15 je H2N(CHR16)CO, gdje je R16 je bočni lanac prirodne D- ili L-amino kiseline;
R1 je (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, 5-indanil, CHR5OCOR6 ili CH2CONR7R8, gdje su R5, R6, R7 i R8 kako je definirano naprijed;
R3 i R4 se svaki nezavisno bira iz grupe koju čine vodik, (C1-C6)alkil, trifluorometil, trifluorometil (C1-C6)alkil, (C1-C6)alkil (difluorometilen), C1-C3)alkil (difluorometilen) C1-C3)alkil, (C6-C10)aril, (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkil, (C6-C10)aril (C6-C10)aril, (C6-C10)aril (C6-C10)aril (C1-C6)alkil, (C3-C6)cikloalkil, (C3-C6)cikloalkil (C1-C6)alkil, hidroksi (C1-C6)alkil, (C1-C10)aciloksi (C1-C6)alkil, (C1-C6)aciloksi (C1-C6)alkil, (C1-C10)acilamino (C1-C6)alkil, piperidil, (C1-C6)alkil piperidil, (C6-C10)aril (C1-C6)alkoksi (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkoksi (C1-C6)alkil, (C1-C6)alkiltio (C1-C6)alkil, (C6-C10)ariltio (C1-C6)alkil, (C1-C6)alkilsulfinil (C1-C6)alkil, (C6-C10)arilsulfinil (C1-C6)alkil, (C6-C10)arilsulfonil (C1-C6)alkil, amino (C1-C6)alkil, (C1-C6)alkilamino (C1-C6)alkil, ((C1-C6)alkilamino)2 (C1-C6)alkil, R17CO(C1-C6)alkil, gdje R17 je R14O ili R7R8N, gdje su R7, R8 i R14 kako je definirano naprijed; ili R18(C1-C6)alkil, gdje je R18 piperazinil, (C1-C10)acil piperazinil, (C6-C10)aril piperazinil, (C5-C9)heteroaril piperazinil, (C1-C6)alkil piperazinil, (C6-C10)aril (C1-C6)alkilpiperazinil, (C5-C9)heteroaril (C1-C6)alkilpiperazinil, morfolinil, tiomorfolinil, piperidinil, pirolidinil, piperidil, (C1-C6)alkil piperidil, (C6-C10)aril piperidil, (C5-C9)heteroaril piperidil, (C6-C10)aril (C1-C6)alkilpiperidil, (C5-C9)heteroaril (C1-C6)alkilpiperidil ili (C1-C10)acilpiperidil; ili
R3 i R4 mogu zajedno formirati (C3-C6)cikloalkil, oksacikloheksil, tiocikloheksil, indanil ili tetralinil prsten ili grupu formule
[image]
gdje je R21 vodik, (C1-C10)acil, (C1-C6)alkil, (C6-C10)aril (C1-C6)alkil, (C5-C9)heteroaril (C1-C6)alkil ili (C1-C6)alkilsulfonil; i
Q je (C1-C6)alkil, (C6-C10)aril, (C6-C10)ariloksi (C6-C10)aril, (C6-C10)aril (C6-C10)aril, (C6-C10)aril (C6-C10)aril (C1-C6)alkil, (C6-C10)ariloksi (C5-C9)heteroaril, (C5-C9)heteroaril, (C1-C6)alkil (C6-C10)aril, (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C1-C6)alkil, (C5-C9)heteroariloksi (C6-C10)aril, (C1-C6)alkil (C5-C9)heteroaril, (C1-C6)alkoksi (C5-C9)heteroaril, (C6-C10)aril (C1-C6)alkoksi (C5-C9)heteroaril, (C5-C9)heteroariloksi (C5-C9)heteroaril, (C6-C10)ariloksi (C1-C6)alkil, (C5-C9)heteroariloksi (C1-C6)alkil, (C1-C6)alkil (C6-C10)ariloksi (C6-C10)aril, (C1-C6)alkil (C5-C9)heteroariloksi (C6-C10)aril, (C1-C6)alkil (C6-C10)ariloksi (C5-C9)heteroaril, (C1-C6)alkoksi (C6-C10)ariloksi (C6-C10)aril, (C1-C6)alkoksi (C5-C9)hetreoariloksi (C6-C10)aril ili (C1-C6)alkoksi (C6-C10)ariloksi (C5-C9)heteroaril, gdje svaka aril grupa je po izboru supstituirana sa fluoro, kloro, bromo, (C1-C6)alkil, (C1-C6)alkoksi ili perfluoro (C1-C6)alkil;
uz predpsotavku da X mora biti supstituiran kada je definiran kao azetidinil, pirolidinil, morfolinil, tiomorfolinil, indolinil, izoidnolinil, tetrahidrohinolinil tetrahidroizohinolinil, piperazinil, (C1-C10)acilpiperazinil, (C1-C6)alkilpiperazinil, (C6-C10)arilpiparazinil, (C5-C9)heteroarilpiperazinil ili premošten diazabicikloalkil prsten.
2. Spoj prema zahtjevu 1, naznačen time što n je 2.
3. Spoj prema zahtjevu 1, naznačen time što bilo koji od R3 ili R4 nije vodik.
4. Spoj prema zahtjevu 1, naznačen time što Q je (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C6-C10)aril, fenoksi (C6-C10)aril, 4-fluorofenoksi (C6-C10)aril, 4-fluorobenziloksi (C6-C10)aril ili (C1-C6)alkil (C6-C10)ariloksi (C6-C10)aril.
5. Spoj prema zahtjevu 1, naznačen time što je X indolinil ili piperidinil.
6. Spoj prema zahtjevu 1, naznačen time što tamo gdje n je 2; bilo koji od R3 ili R4 nije vodik; Q je (C1-C6)alkoksi (C6-C10)aril, (C6-C10)aril (C1-C6)alkoksi (C6-C10)aril, 4-fluorofenoksi (C6-C10)aril, fenoksi (C6-C10)aril, 4-fluorobenziloksi (C6-C10)aril ili (C1-C6)alkil (C6-C10)ariloksi (C6-C10)aril; i X je indolinil ili piperidinil.
7. Spoj prema zahtjevu 1, naznačen time što se spomenuti spoj bira iz grupe koju čine slijedeći spojevi:
indan-5-il estar 3-[(cikloheksilhidroksikarbamoilmetil)-(4-metoksibenzensulfonil)-amino]-propionske kiseline;
1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzen-sulfonil)-amino]propionil}piperidin-4-il estar octene kiseline;
2-cikloheksil-N-hidroksi-2-[[3-(4-hidroksipiperidin-1-il)-3-okso-propil]-(4-metoksi-benzensulfonil)amino] acetamid;
1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzen-sulfonil)amino]propionil}piperidin-4-il estar benzoeve kiseline;
N-hidroksi-2-[[3-(4-hidroksipiperidin-1-il)-3-oksopropil]-(4-metoksi-benzensulfonil)amino]-3-metilbutiramid;
1-{3-[(cikloheksil-hidroksikarbamoil-metil)-(4-metoksi-benzen-sulfonil)amino]propionil}piperidin-4-karboksilna kiselina;
etil estar 1-{3-[(cikloheksil-hidroksikarbamoil-metil)-(4-metoksi-benzen-sulfonil)-amino]propionil}piperidin-4-karboksilne kiseline;
2-cikloheksil-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-aminopiperidin-1-il)-3-oksipropil]amino} acetamid;
3-(4-klorofenil)-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-aminopiperidin-1-il)-3-oksipropil] amino}propionamid;
3-cikloheksil-N-hidroksi-2-{(4-metoksibenzensulfonil)-[3-(4-metil-aminopiperidin-1-il)-3-oksipropil]amino} propionamid;
N-hidroksi-2-[{3-[4-(2-hidroksi-2-metilpropil)piperazin-1-il]-3-oksopropil}-(4-metoksi-benzensulfonil)amino]-3-metilbutiramid;
2-(4-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzensulfonil)-amino]propionil}piperazin-1-il)-etil estar 2,2-dimetilpropionske kiseline;
2-(4-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzensulfonil)-amino]propionil}piperazin-1-il)-etil estar benzoeve kiseline.
2-cikloheksil-N-hidroksi-2-[{3-[4-(2-hidroksietil)piperidin-1-il]-3-oksopropil}-(4-metoksibenzensulfonil) amino] acetamid;
2-hidroksi-2-[{3-[5-(2-hidroksietil)-2,5-diazabiciklo[2,2,1]-hept-2-il]-3-oksopropil}-(4-metoksi-benzensulfonil) amino]-3-metilbutiramid;
2-{(4-benziloksibenzensulfonil)-[3-(4-hidroksipiperidin-1-il)-3-oksopropil]amino}-N-hidroksi-3-metilbutiramid;
2-cikloheksil-2-{[4-(4-fluorofenoksi)benzensulfonil]-[3-(4-hidroksi-piperidin-1-il)-3-oksopropil]-amino}-N-hidroksiacetamid;
2-{[4-(4-butilfenoksi)benzensulfonil]-[3-(4-hidroksipiperidin-1-il)-3-oksopropil]-amino}-N-hidroksi-3-metilbutiramid;
hidroksamid 1-{(4-metoksibenzensulfonil)-[3-(4-metilaminopiperidin-1il)-3-okso-propil]amino}-ciklopentankarboksilne kiseline;
etil estar 4-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-metoksi-benzen-sulfonil)amino]-propionil}piperazin-2-karboksilne kiseline;
etoksikarboniloksimetil estar 3-[(cikloheksil-hidroksikarbamoil-metil)-(4-metoksi-benzen-sulfonil)amino] propionske kiseline;
etoksikarboniloksimetil estar 3-[(1-hidroksikarbamoilpentil)-(4-metoksi-benzensulfonil)amino]propionske kiseline;
1-{3-[(1-hidroksikarbamoil-2-metilpropil)-(4-fenoksi-benzensulfonil)-amino]propionil}piperidin-4-karboksilna kiselina;
etoksikarboniloksimetil estar 3-[[4-(4-fluorobenziloksi)-benzensulfonil]-(1-hidroksi-karbamoil-2-metil-propil)-amino]-propionske kiseline; i
etoksikarboniloksimetil estar 3-[[4-(4-fluorofenoksi)-benzensulfonil]-(1-hidroksi-karbamoil-2-metil-propil)-amino]-propionske kiseline.
8. Farmaceutski preparat za: (a) tretiranje stanja odabranog iz grupe koju čine artritis, karcinom, ulcer tkiva, makularna degeneracija, restenozis, periodontalno oboljenje, epidermolizis bulosa, skleritis, u kombinaciji sa standardnim NSAID'S i analgeticama i u kombinaciji sa drugim citoksičnim antikarcinomnim agensima, i za druga oboljenja koja su karakterizirana sa aktivnošću matrične metaloproteinaze, AIDS, sepsis, septični šok i druga oboljenja koja obuhvaćaju proizvodnju faktora tumorne nekroze (TNF); ili (b) inhibiciju matričnih metaloproteinaza ili proizvodnje faktora tumorne nekroze (TNF) kod sisavaca, uključujući i ljude, naznačen time što obuhvaća takvu količinu spoja prema zahtjevu 1, koja je efikasna u takvom tretmanom i farmaceutski prihvatljiv nosač.
9. Postupak za inhibiciju: (a) matričnih metaloproteinaza; ili (b) inhibiciju proizvodnje faktora tumorne nekroze (TNF) kod sisavaca, uključujući i ljude, naznačen time što obuhvaća primjenu kod spomenutih sisavaca efikasnu količinu spoja prema zahtjevu 1.
10. Postupak za tretiranje stanja odabranog iz grupe koju čine artritis, karcinom, ulcer tkiva, makularna degeneracija, restenozis, periodontalno oboljenje, epidermolizis bulosa, skleritis, spojevi formule I mogu se koristiti u kombinaciji sa standardnim NSAID'S i analgeticima, te u kombinaciji sa citotoksičnim antikarcinomnim agensima, i za druga oboljenja koja su karaketrizirana sa aktivnošću matrične metaloproteinaze, AIDS, sepsis, sepstični šok i druga oboljenja koja obuhvaćaju proizvodnju faktora tumorne nekroze (TNF) kod sisavaca, uključujući i ljude, naznačen time što obuhvaća primjenu kod spomenutih sisavaca takvu količine spoja prema zahtjevu 1, koja je efikasna u tretiranju takvog stanja.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2467596P | 1996-08-23 | 1996-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP970453A2 true HRP970453A2 (en) | 1998-08-31 |
Family
ID=21821806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR60/024,675A HRP970453A2 (en) | 1996-08-23 | 1997-08-22 | Arylsulfonylamino hydroxamic acid derivatives |
Country Status (31)
Country | Link |
---|---|
US (1) | US6153609A (hr) |
EP (1) | EP0922030A1 (hr) |
JP (1) | JP2000501423A (hr) |
KR (1) | KR20000068248A (hr) |
CN (1) | CN1228083A (hr) |
AP (1) | AP733A (hr) |
AR (1) | AR009292A1 (hr) |
AU (1) | AU711585B2 (hr) |
BG (1) | BG103191A (hr) |
BR (1) | BR9711223A (hr) |
CA (1) | CA2264284A1 (hr) |
CO (1) | CO4600003A1 (hr) |
EA (1) | EA199900139A1 (hr) |
GT (1) | GT199700094A (hr) |
HN (1) | HN1997000110A (hr) |
HR (1) | HRP970453A2 (hr) |
ID (1) | ID18063A (hr) |
IL (1) | IL128189A0 (hr) |
IS (1) | IS4958A (hr) |
MA (1) | MA24307A1 (hr) |
NO (1) | NO990821L (hr) |
OA (1) | OA10978A (hr) |
PA (1) | PA8435301A1 (hr) |
PE (1) | PE99698A1 (hr) |
PL (1) | PL331895A1 (hr) |
SK (1) | SK21499A3 (hr) |
TN (1) | TNSN97139A1 (hr) |
TR (1) | TR199900387T2 (hr) |
TW (1) | TW397823B (hr) |
WO (1) | WO1998007697A1 (hr) |
ZA (1) | ZA977561B (hr) |
Families Citing this family (287)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
US6153757A (en) * | 1995-12-08 | 2000-11-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors and intermediates useful for their preparation |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
WO1998050348A1 (en) * | 1997-05-09 | 1998-11-12 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
AUPO721997A0 (en) * | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
DE69805473T2 (de) * | 1997-08-08 | 2003-01-16 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsäurederivate |
PA8469301A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimientos para la preparacion de acidos hidroxamicos. |
PT952148E (pt) * | 1998-04-10 | 2004-09-30 | Pfizer Prod Inc | Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico |
GT199900044A (es) * | 1998-04-10 | 2000-09-14 | Procedimientos para preparar haluros de fenoxifenilsulfonilo. | |
PA8469601A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para alquilar sulfonamidas impedidas estericamente |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
BR0007784A (pt) | 1999-01-27 | 2002-02-05 | American Cyanamid Co | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
EP1041072B1 (en) * | 1999-03-31 | 2003-07-16 | Pfizer Products Inc. | Dioxocyclopentyl hydroxamic acids |
DE19920907A1 (de) * | 1999-05-06 | 2000-11-09 | Basf Ag | Verfahren zur Herstellung eines Cyclohexylglycin-Bausteins |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
SE0000382D0 (sv) | 2000-02-07 | 2000-02-07 | Astrazeneca Ab | New process |
US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
US6458822B2 (en) | 2000-03-13 | 2002-10-01 | Pfizer Inc. | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
HUP0302525A2 (hu) | 2001-01-05 | 2003-10-28 | Abgenix, Inc. | Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok |
US6995171B2 (en) | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
JP2005507937A (ja) | 2001-11-01 | 2005-03-24 | ワイス・ホールディングズ・コーポレイション | マトリックスメタロプロテイナーゼおよびtace阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸 |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
WO2003055851A1 (fr) * | 2001-12-27 | 2003-07-10 | Sumitomo Pharmaceuticals Company, Limited | Derives d'acide hydroxamique et inhibiteur des mmp contenant ces derniers en tant que substance active |
JP2005527511A (ja) | 2002-03-01 | 2005-09-15 | ファイザー インコーポレイテッド | 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法 |
EP1485131A1 (en) * | 2002-03-08 | 2004-12-15 | Novartis AG | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
PT1585743E (pt) | 2002-12-19 | 2007-07-12 | Pfizer | Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas. |
AU2003294917A1 (en) * | 2002-12-20 | 2004-07-14 | Novartis Ag | Device and method for delivering mmp inhibitors |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
ES2401330T3 (es) | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
JP4593559B2 (ja) * | 2003-03-25 | 2010-12-08 | ラボラトワール フルニエ エス・アー | ベンゼンスルホンアミド誘導体、その製造方法、及び、痛みを治療するためのその使用 |
MXPA06001634A (es) | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
BRPI0413876A (pt) | 2003-08-29 | 2006-10-24 | Pfizer | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
AR055057A1 (es) | 2005-05-18 | 2007-08-01 | Array Biopharma Inc | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
CN101454004B (zh) | 2006-04-18 | 2013-12-04 | 阿迪亚生命科学公司 | 作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类 |
WO2008075196A1 (en) | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Benzimidazole derivatives |
JP5491199B2 (ja) | 2007-01-19 | 2014-05-14 | アルデア バイオサイエンシズ,インコーポレイティド | Mekのインヒビター |
CN101678215B (zh) | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
EP2175885B1 (en) | 2007-07-30 | 2016-10-12 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
PT2690101E (pt) | 2007-12-19 | 2015-10-08 | Genentech Inc | 5-anilinoimidazopiridinas e métodos de utilização |
EP2220092B1 (en) | 2007-12-21 | 2012-06-06 | Genentech, Inc. | Azaindolizines and methods of use |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
JP5613657B2 (ja) | 2008-03-28 | 2014-10-29 | ヘイル バイオファーマ ベンチャーズ,エルエルシー | ベンゾジアゼピン組成物の投与 |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
JP5836125B2 (ja) | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用 |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
IL271761B (en) | 2009-02-05 | 2022-09-01 | Immunogen Inc | (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepine-6-one, 4-benzyloxy-5-methoxy -2-nitrobenzoic acid and a process for their preparation |
CA2748943A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US20100222381A1 (en) | 2009-02-27 | 2010-09-02 | Hariprasad Vankayalapati | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
WO2010108652A1 (en) | 2009-03-27 | 2010-09-30 | Ardea Biosciences Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011014726A1 (en) | 2009-07-31 | 2011-02-03 | Osi Pharmaceuticals, Inc. | Mtor inhibitor and angiogenesis inhibitor combination therapy |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
AU2010306830C1 (en) | 2009-10-13 | 2015-05-28 | Allomek Therapeutics Llc | Novel mek inhibitors, useful in the treatment of diseases |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
MY173795A (en) | 2009-11-05 | 2020-02-24 | Incozen Therapeutics Pvt Ltd | Novel benzopyran kinase modulators |
AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
DK3150610T3 (da) | 2010-02-12 | 2019-11-04 | Pfizer | Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
EP2519826A2 (en) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物 |
ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
CA2802857C (en) | 2010-06-16 | 2018-09-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Antibodies to endoplasmin and their use |
WO2012052948A1 (en) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Pyridine- 2- derivatives as smoothened receptor modulators |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
EP2671082B1 (en) | 2011-02-02 | 2020-01-15 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
RU2748733C2 (ru) | 2011-02-15 | 2021-05-31 | Иммуноджен, Инк. | Цитотоксические производные бензодиазепина |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
WO2012145183A2 (en) | 2011-04-19 | 2012-10-26 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
MY168757A (en) | 2011-05-04 | 2018-12-04 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
CN107737100A (zh) | 2011-06-14 | 2018-02-27 | 哈尔生物药投资有限责任公司 | 苯二氮卓组合物的投与 |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
ES2834093T3 (es) | 2011-07-21 | 2021-06-16 | Sumitomo Dainippon Pharma Oncology Inc | Inhibidores de proteína quinasa heterocíclicos |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
JP5914667B2 (ja) | 2011-09-22 | 2016-05-11 | ファイザー・インク | ピロロピリミジンおよびプリン誘導体 |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
CA2848842C (en) | 2011-10-04 | 2020-09-29 | King's College London | Ige anti -hmw-maa antibody |
CN104271599A (zh) | 2011-11-08 | 2015-01-07 | 辉瑞公司 | 使用抗m-csf抗体治疗炎性疾病的方法 |
ES2668044T3 (es) | 2012-02-22 | 2018-05-16 | The Regents Of The University Of Colorado, A Body Corporate | Derivados de bouvardina y usos terapéuticos de los mismos |
US9452215B2 (en) | 2012-02-22 | 2016-09-27 | The Regents Of The University Of Colorado | Bourvadin derivatives and therapeutic uses thereof |
WO2013144737A2 (en) | 2012-03-30 | 2013-10-03 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
EP4074728A1 (en) | 2012-08-31 | 2022-10-19 | Sutro Biopharma, Inc. | Modified peptides comprising an azido group |
DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
ES2691742T5 (es) | 2012-11-01 | 2022-03-18 | Infinity Pharmaceuticals Inc | Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa |
JP6423804B2 (ja) | 2013-02-28 | 2018-11-14 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
EP2961434A2 (en) | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
PT2970205T (pt) | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
TW201524952A (zh) | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Kras g12c之共價抑制劑 |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
US20160113932A1 (en) | 2013-05-30 | 2016-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
EP3052096B8 (en) | 2013-10-03 | 2018-03-07 | Kura Oncology, Inc. | Inhibitors of erk and methods of use |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
CN106488910B (zh) | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
BR112016024513A2 (pt) | 2014-04-30 | 2017-08-15 | Pfizer | derivados de di-heterociclo ligados à cicloalquila |
BR112016029662B1 (pt) | 2014-06-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
JP6811706B2 (ja) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Epha4に対するヒトモノクローナル抗体及びそれらの使用 |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Kras g12c変異体タンパク質のインヒビター |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
ES2746839T3 (es) | 2014-12-18 | 2020-03-09 | Pfizer | Derivados de pirimidina y triazina y su uso como inhibidores de AXL |
AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
MX2017013956A (es) | 2015-05-01 | 2018-09-05 | Cocrystal Pharma Inc | Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer. |
US9758539B2 (en) | 2015-05-18 | 2017-09-12 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
CN108289861B (zh) | 2015-08-03 | 2021-11-02 | 大日本住友制药肿瘤公司 | 用于治疗癌症的组合疗法 |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
CA3006743A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
EP3407917A1 (en) | 2016-01-27 | 2018-12-05 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
JP6919977B2 (ja) | 2016-03-16 | 2021-08-18 | クラ オンコロジー,インク. | メニン−mllの置換された阻害剤及びその使用方法 |
SG11201807834WA (en) | 2016-03-16 | 2018-10-30 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
CA3024556A1 (en) | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
US11118233B2 (en) | 2016-05-18 | 2021-09-14 | The University Of Chicago | BTK mutation and ibrutinib resistance |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
WO2018119000A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
WO2018137705A1 (en) | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
WO2018218071A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
EP3658588A1 (en) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン |
US10596270B2 (en) | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
WO2019094773A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
AU2018378935A1 (en) | 2017-12-07 | 2020-06-25 | The Regents Of The University Of Michigan | NSD family inhibitors and methods of treatment therewith |
MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3790886A1 (en) | 2018-05-10 | 2021-03-17 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
MA52765A (fr) | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
CN112533581A (zh) | 2018-06-07 | 2021-03-19 | 密歇根大学董事会 | Prc1抑制剂及用其进行治疗的方法 |
WO2019241157A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
JP2021532157A (ja) | 2018-08-01 | 2021-11-25 | アラクセス ファーマ エルエルシー | がんを処置するための複素環式スピロ化合物およびその使用方法 |
JP2022500454A (ja) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体抗体コンジュゲートによる併用療法 |
KR20210083286A (ko) | 2018-10-24 | 2021-07-06 | 아락세스 파마 엘엘씨 | 종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CA3120383A1 (en) | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
US20220056015A1 (en) | 2018-12-20 | 2022-02-24 | Amgen Inc. | Kif18a inhibitors |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
CR20210387A (es) | 2018-12-20 | 2021-08-19 | Amgen Inc | Inhibidores de kif18a |
JP2022514268A (ja) | 2018-12-20 | 2022-02-10 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
CN113412262A (zh) | 2019-02-12 | 2021-09-17 | 大日本住友制药肿瘤公司 | 包含杂环蛋白激酶抑制剂的制剂 |
MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
SG11202109036WA (en) | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
WO2021055728A1 (en) | 2019-09-18 | 2021-03-25 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為menin抑制劑之六氫吡啶化合物 |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
JP7340100B2 (ja) | 2019-10-28 | 2023-09-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Kras g12c変異型の小分子阻害薬 |
CN115551500A (zh) | 2019-10-31 | 2022-12-30 | 大鹏药品工业株式会社 | 4-氨基丁-2-烯酰胺衍生物及其盐 |
CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
AU2020383535A1 (en) | 2019-11-14 | 2022-05-05 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
AU2020381492A1 (en) | 2019-11-14 | 2022-05-26 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
EP4087611A1 (en) | 2020-01-07 | 2022-11-16 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
CN116113406A (zh) | 2020-07-10 | 2023-05-12 | 密歇根大学董事会 | Gas41抑制剂及其使用方法 |
US20230255972A1 (en) | 2020-07-15 | 2023-08-17 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
AR125490A1 (es) | 2021-04-30 | 2023-07-19 | Celgene Corp | Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi) |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
CN117769554A (zh) | 2021-05-28 | 2024-03-26 | 大鹏药品工业株式会社 | Kras突变蛋白的小分子抑制剂 |
WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023211812A1 (en) | 2022-04-25 | 2023-11-02 | Nested Therapeutics, Inc. | Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024010925A2 (en) | 2022-07-08 | 2024-01-11 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB2303850B (en) * | 1994-06-22 | 1998-06-10 | British Biotech Pharm | Metalloproteinase inhibitors |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1997005865A1 (en) * | 1995-08-08 | 1997-02-20 | Fibrogen, Inc. | C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen |
US5994351A (en) * | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
-
1997
- 1997-07-25 IL IL12818997A patent/IL128189A0/xx unknown
- 1997-07-25 US US09/242,504 patent/US6153609A/en not_active Expired - Fee Related
- 1997-07-25 SK SK214-99A patent/SK21499A3/sk unknown
- 1997-07-25 EA EA199900139A patent/EA199900139A1/ru unknown
- 1997-07-25 BR BR9711223A patent/BR9711223A/pt unknown
- 1997-07-25 JP JP10510535A patent/JP2000501423A/ja active Pending
- 1997-07-25 AU AU34563/97A patent/AU711585B2/en not_active Ceased
- 1997-07-25 EP EP97930699A patent/EP0922030A1/en not_active Withdrawn
- 1997-07-25 CN CN97197354A patent/CN1228083A/zh active Pending
- 1997-07-25 TR TR1999/00387T patent/TR199900387T2/xx unknown
- 1997-07-25 WO PCT/IB1997/000924 patent/WO1998007697A1/en not_active Application Discontinuation
- 1997-07-25 KR KR1019997001383A patent/KR20000068248A/ko not_active Application Discontinuation
- 1997-07-25 PL PL97331895A patent/PL331895A1/xx unknown
- 1997-07-25 CA CA002264284A patent/CA2264284A1/en not_active Abandoned
- 1997-08-06 PA PA19978435301A patent/PA8435301A1/es unknown
- 1997-08-18 PE PE1997000727A patent/PE99698A1/es not_active Application Discontinuation
- 1997-08-19 GT GT199700094A patent/GT199700094A/es unknown
- 1997-08-20 TW TW086112058A patent/TW397823B/zh active
- 1997-08-20 TN TNTNSN97139A patent/TNSN97139A1/fr unknown
- 1997-08-21 AR ARP970103803A patent/AR009292A1/es unknown
- 1997-08-21 AP APAP/P/1997/001078A patent/AP733A/en active
- 1997-08-21 CO CO97048269A patent/CO4600003A1/es unknown
- 1997-08-21 MA MA24774A patent/MA24307A1/fr unknown
- 1997-08-21 ID IDP972918A patent/ID18063A/id unknown
- 1997-08-22 HR HR60/024,675A patent/HRP970453A2/hr not_active Application Discontinuation
- 1997-08-22 ZA ZA977561A patent/ZA977561B/xx unknown
- 1997-08-30 HN HN1997000110A patent/HN1997000110A/es unknown
-
1999
- 1999-01-26 IS IS4958A patent/IS4958A/is unknown
- 1999-02-19 OA OA9900036A patent/OA10978A/en unknown
- 1999-02-22 BG BG103191A patent/BG103191A/xx unknown
- 1999-02-22 NO NO990821A patent/NO990821L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PA8435301A1 (es) | 1999-12-27 |
AU3456397A (en) | 1998-03-06 |
CN1228083A (zh) | 1999-09-08 |
EA199900139A1 (ru) | 1999-08-26 |
IS4958A (is) | 1999-01-26 |
MA24307A1 (fr) | 1998-04-01 |
NO990821L (no) | 1999-02-23 |
SK21499A3 (en) | 2000-05-16 |
ID18063A (id) | 1998-02-26 |
TW397823B (en) | 2000-07-11 |
BG103191A (en) | 1999-11-30 |
BR9711223A (pt) | 1999-08-17 |
AU711585B2 (en) | 1999-10-14 |
AP9701078A0 (en) | 1997-10-31 |
PL331895A1 (en) | 1999-08-16 |
JP2000501423A (ja) | 2000-02-08 |
TNSN97139A1 (fr) | 2005-03-15 |
US6153609A (en) | 2000-11-28 |
PE99698A1 (es) | 1998-12-26 |
OA10978A (en) | 2001-11-05 |
GT199700094A (es) | 1999-02-10 |
IL128189A0 (en) | 1999-11-30 |
NO990821D0 (no) | 1999-02-22 |
TR199900387T2 (xx) | 1999-04-21 |
ZA977561B (en) | 1999-02-22 |
WO1998007697A1 (en) | 1998-02-26 |
CA2264284A1 (en) | 1998-02-26 |
AR009292A1 (es) | 2000-04-12 |
CO4600003A1 (es) | 1998-05-08 |
KR20000068248A (ko) | 2000-11-25 |
HN1997000110A (es) | 1998-02-26 |
EP0922030A1 (en) | 1999-06-16 |
AP733A (en) | 1999-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP970453A2 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
AP1220A (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives. | |
EP0821671B1 (en) | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors | |
AP958A (en) | Arylsulfonyl hydroxamic acid derivatives. | |
RU2145597C1 (ru) | Производные арилсульфониламиногидроксамовой кислоты, способ их получения, фармацевтическая композиция, способ ингибирования матричных металлопротеиназ и способ лечения | |
HRP980058A2 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
EP0895988B1 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
NZ299659A (en) | Amidine derivatives; compounds, preparation and medicaments with anti-thrombin activity | |
AU776171B2 (en) | Alpha-amino-beta-sulfonyl hydroxamic acid compounds | |
US6380219B1 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
KR0173035B1 (ko) | 선택적 트롬빈 억제제 | |
US6509337B1 (en) | Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors | |
US6486193B2 (en) | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | |
MXPA99001808A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
US6107337A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
CZ58999A3 (cs) | Deriváty arylsulfonylaminohydroxamové kyseliny, farmaceutický prostředek, způsob inhibice matričních metalloproteinas nebo produkce faktoru nekrosy nádorů a způsob léčení |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
A1OB | Publication of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 19990822 Year of fee payment: 3 |
|
ODBC | Application rejected |